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Taxanes are highly active cytotoxic agents predominantly administered by intravenous (i.v) route. 
The solvents required for the i.v administration of the taxane drugs (cremophor EL and Tween80) 
are associated with high toxicity and also reduced clinical efficacy of the drugs. Oral 
chemotherapy is now preferred over parenteral administration owing to patience’s preference, 
convenience, flexibility of timing and location of administration. Prolonged drug exposure with 
reduced toxicity as compared to prolonged infusion can be achieved by oral chemotherapy. But, 
most anticancer drugs have very low oral bioavailability due to their high affinity for the 
multidrug efflux pump P-glycoprotein (P-gp) and cytochrome P450 (CYP) isoenzymes in the liver 
and/or gut wall. Nanoparticle (NP) technology could be efficiently employed to overcome the P-
gp recognition and thus bear the most potential to enhance the oral bioavailability of drugs that 
are otherwise poorly absorbed when administered orally. Their submicron size and their large 
specific surface area favor their absorption compared to larger carrier. Many strategies have been 
developed to improve mucosal absorption of NPs, either by modifying their surface properties or 
by coupling a targeting molecule at their surface.   In the present study, a novel NP formulation, 
i.e. biodegradable Poly(lactide)-vitamin E TPGS (PLA-TPGS) NPs incorporated with a medical 
clay, montmorillonite (MMT) (named PLA-TPGS/MMT NPs hereinafter), for oral chemotherapy 
of  docetaxel. D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) is a water-soluble 
derivative of natural vitamin E, which is formed by esterification of vitamin E succinate with 
polyethylene glycol (PEG) 1000. It has a hydrophile–lipophile balance (HLB) of around 13 and 
consists of a tocopherol (vitamin E) hydrophobic group and a PEG hydrophilic group. Such 
characteristics make it an effective emulsifier and a potential surface modifying agent in NP 
technology. High drug entrapment efficiency (EE, up to 100%) and high emulsification efficiency 
(67 times higher than PVA) have been achieved with TPGS. MMT is a potent detoxifier with 
very good adsorbent properties due to its high aspect ratio. MMT can provide mucoadhesive 
capability for the NPs to cross the GI barrier. It has also been used as drug carrier for controlled 
  v
 
release systems and it has been proved to be non toxic by hematological, biochemical and 
histopathological analysis in rat models. Our PLA-TPGS/MMT NP drug delivery system thus 
represents a novel concept in the development of drug delivery systems, i.e. formulating the drug 
carrier from a component material, which has therapeutic effects and also medicates the side 
effects of the encapsulated drugs. This nanoparticle formulation was compared with PLGA, 
PLGA/MMT and PLA-TPGS nanoparticle formulations for its efficiency both in vitro and in 
vivo. The synthesized nanoparticles were all in 200-300nm in size and the drug encapsulation 
efficiency was observed to be the highest (about 80%) in PLA-TPGS and PLA-TPGS/MMT NPs. 
The presence of MMT slightly increased the size and surface charge of the nanoparticles and 
slowed down the release rate of docetaxel which was observed in the in vitro release experiments. 
Also, coumarin-6 encapsulated PLA-TPGS/MMT NPs showed twice the cell uptake efficiency as 
that of PLGA NPs which was attributed to the presence of both MMT and TPGS. This higher 
uptake also resulted in high cytotoxicity of PLA-TPGS/MMT nanoparticles over other NP 
formulations. Further the nanoparticles were studied for their in vivo performance in Sprague 
Dawly rats by administering four nanoparticle formulations and Taxotere® orally. PLA-
TPGS/MMT NPs showed 25 fold higher oral bioavailability than Taxotere®  and increased half 
life in plasma (118 h) when compared to other nanoparticle formulations. The MMT coating on 
the NPs provides a mucoadhesive property and prevents the elimination through the alimentary 
canal. At the same time, the hydrophilic nature of TPGS chains on the NP surface and the smaller 
size of PLA-TPGS and PLA-TPGS/MMT NPs enable it to pass through the mucus network, 
unlike the PLGA and PLGA/MMT NPs that could have permanently adhered to the mucus 
network and eliminated during mucus clearance. Thus the mucoadhesive property of MMT and 
hydrophilic nature of PLA-TPGS copolymer could hace acted synergistically resulting in a very 
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 CHAPTER 1. INTRODUCTION 
 
1.1 General Background 
Cancer is a group of more than 100 diseases characterized by rapid cell growth caused by up 
regulation of oncogenes or down regulation of tumor suppressor genes (particularly p53 gene, 
responsible for 50% of human cancers) and angiogenesis (in solid tumors), a process that aims at 
supplying  blood to growing cancer tissues. Cancer cells are derived from normal cells and hence 
they are not recognized by the immune system. A tumor, or mass of cells formed of these 
abnormal cells, may remain within the tissue from which it originated (a condition called ‘in situ 
cancer’), or it may invade nearby tissues (a condition called ‘invasive cancer’). An invasive tumor 
is said to be malignant and the cells shed into the blood or lymph are likely to establish new 
tumors throughout the body (metastasis).  
By 2020, the World Health Organization (WHO) estimates that, globally, more than 15 million 
people will experience cancer and 10 million people will die from it each year that accounts for a 
60% increase in deaths [1]. According to World Health Organization, Asia's prevalence of cancer 
deaths may climb 45 percent from about 112 per 100,000 in 2005 to 163 per 100,000 people by 
2030. At this rate, it would overtake the cancer prevalence in America, where cancer-related 
mortalities are expected to rise to 156 per 100,000 from 136 per 100,000 over the same period. 
Europe, which has the highest prevalence at 215 per 100,000, may increase about 9 percent to 
234 per 100,000. Hence, there is growing concern in treating this dreadful disease.  
Fighting cancer is like fighting in a war. There are several strategies (modality) to fight this 
enemy and most often a multi-modality approach is used. Some of the strategies are listed below. 
All the multi-modality approaches definitely include chemotherapy, synergistic with any other 
kind of approach (adjuvant chemotherapy).  
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 • Surgery  
• Chemotherapy  
• Radiation Therapy  
• Hormonal Therapy  
• Immunotherapy  
• Bone Marrow Transplantation  
• Experimental Treatments  
• Pain Management  
• Palliative Treatments  
• Alternative Treatments  
• Hospice  
Effective cancer chemotherapeutic treatment can be considered as a ‘5 year disease free survival’ 
of a cancer patient. Chemotherapy can be more successful by treating it as a chronic disease, if 
the cancer is diagnosed at an earlier stage. 
Anti-cancer drugs can be broadly categorized into two: 
(i) Cell cycle specific drug 
(ii) Cell cycle non-specific drug 
These anticancer drugs target the unique processes occurring in cancer cells like rapid cell 
growth, angiogenesis, metastasis, cancer cell specific markers or defective gene products. 
Sometimes, few characteristics are common between the cancer cells and the normal cells, 
especially bone marrow cells, cells of gastro-intestinal mucosa, hair follicles and fetus. 
Moreover great care has to be taken while determining the dosing regimen of these anticancer 
drugs. It should be determined based on the growth fraction and the doubling time of the cancer 
cells. Above all, the cancer cells also gain drug resistance, thus making chemotherapy ineffective. 
The success of chemotherapy also depends on the patient’s condition. Most anticancer drugs 
cause bone marrow suppression and depending on bone marrow capacity, the dosing regimen is 
decided. Further, most anticancer drugs are metabolized in liver and are eliminated in the urine 
and so the liver and kidney play a major functional role. 
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 Though there are several anticancer drugs with different mechanism of action, the desired success 
of targeting the cancer cells from different directions is yet to be achieved. Hence, it is not 
enough to discover compounds that kill cancer cells. 
Thus, an effective chemotherapy can be achieved by administering the anticancer drug in a well 
defined dosing regimen at the targeted site with lesser side effects. This cannot be achieved with 
the currently existing formulations since they have their own disadvantages. Researchers have 
been constantly working on the drug vehicles to achieve efficacy and to eliminate the 
disadvantages. Here one such way has been considered. Oral delivery of nanoparticles, that 
encapsulate these anticancer drugs, has been proposed as a promising tactic to overcome some of 
the challenges addressed above. Oral route of drug administration can improve the efficiency of 
chemotherapy, by maintaining appropriate drug concentrations in the circulation for extended 
duration of time, together with patient’s convenience. It can further combat the side effects of the 
drug excipients (cremophor EL and polysorbate 80). 
 
 
1.2 Objectives  
The objective of my research was to develop an oral formulation for the anticancer drug 
docetaxel, without compromising its bioavailability as well as without using any immune 
suppressor agents (P-gp inhibitors). Nanoparticle technology has been efficiently utilized for this 
purpose. Docetaxel (taxane) has been encapsulated in a mucoadhesive biodegradable (PLA-
TPGS/MMT) polymeric system to form nanoparticles and has been physically characterized for 
its size, zeta potential, morphology, drug content and drug release properties. The efficiency of 
these nanoparticles have been tested in vitro in human tumor cell lines (Caco-2 and MCF-7). The 





 1.3  Thesis Organization 
The body of the thesis is organized into five chapters. Chapter one gives a brief introduction to 
the project. It comprises of general background, as well as objectives of the project. Chapter two 
is a collection of information from the literature, which has formed the basis for this research 
idea. In chapter three, the various materials and methods used in this experiment are described. 
The experimental results and discussions are elaborated in chapter four. Finally the conclusions 
















 CHAPTER 2. LITERATURE REVIEW 
 
2.1  Evolution of Cancer Chemotherapy 
The use of chemotherapy to treat cancer began in the 20th century. The famous German Chemist 
Paul Ehrlich set about developing drugs to treat infectious diseases. He was the one who coined 
the term “chemotherapy” and defined it as the use of chemicals to treat infectious diseases. The 
history begins with the accidental discovery of nitrogen mustard (chemical warfare agent) as an 
effective anticancer agent by two pharmacogist, Louis S.Goodman and Alfred Gilman. Shortly 
after the second world war, it was followed by the use of folic acid to treat acute lymphoblastic 
leukemia. Aminopterin and methotrexate, analogues of folic acid were then used. Later several 
anti metabolites and alkaloids were used to treat cancer. This is followed by the discovery of 
several anticancer agent which had been classified according to their mechanism of action in table 
2.1. The figure 2.1 briefly describes how cancer chemotherapy has evolved through years.  
 






Figure 2.1: Timeline of events in the development of cancer chemotherapy [2] (continued) 
 
2.2  Classification of Anti-cancer Drugs 
Table 2.1 Classification of anti-cancer drugs 
ACTION SITE MECHANISM DRUG 
Prevent DNA 
synthesis 
Block nucleotide synthesis(both 
purines and pyrimidines) 
Inhibit dihydrofolate 
reductase Methotrexate 
Block purine synthesis 
“Pseudofeedback 





Block pyrimidine synthesis Inhibit thymidylate synthase 5-Fluorouracil 




























Intercalate or form 






Cause DNA strand 
breaks 






Inhibit topoisomerase I Irinotecan 
Generate H2O2 (??) Procarbazine 
Interrupt 


































































Decrease LH and FSH 
secretion 
Miscellaneous Arsenic trioxide 




GnRH antagonist Abarelix 
 Bicalutamide Flutamide 
Prevent estrogen 





Anti-estrogens SERMS Tamoxifen Toremifiene 
Anti-estrogens SERD Fulvestrant 
 
2.3  Taxanes 
The taxanes have played a significant role in the treatment of various malignancies over 
the past two decades. Paclitaxel and docetaxel are approved for clinical use by the Food 
and Drug Administration (FDA) board for the treatment of breast cancer, ovarian cancer, 
non small-cell lung cancer and prostate cancer. The taxanes are a unique class of 
hydrophobic anti neoplastic agents that exhibit cytotoxic activity by binding to tubulin 
and promoting inappropriately stable, non-functional microtubule formation [3]. Figure 




Figure 2.2 (a) Structure of a cell, with microtubules playing a role in the many cellular functions. (b) 
During mitosis replicated chromosomes are positioned near the middle of the cytoplasm and then 
segregated so that each daughter cell receives a copy of the original DNA. To do this cells utilize 
microtubules (referred to as the spindle apparatus) to pull chromosomes into each cell. The centrioles 
are paired cellular organelle which functions in the organization of the mitotic spindle during cell 
division in eukaryotes. (c) Microtubules are composed of heterodimers of alpha- and beta-tubulin. 
Paclitaxel binds to beta-tubulin on the inner surface of the microtubule, stabilizing it and blocking its 
normal dynamics. (d) Illustration of a surfactant vehicle. The surfactant heads are hydrophilic 
moieties and the surfactant tails are hydrophobic moieties. According to the drug hydrophobicity, 
there may be different loci of solubilization in surfactant micelles.[4] 
 
Paclitaxel was first discovered in the early 1960s as a part of National Cancer Institute screening 
study to identify natural compounds with anti-cancer properties. Paclitaxel was isolated as a crude 
extract from the bark of the North American pacific yew tree, Taxus brevifolia, and was found to 
possess excellent cytotoxic effects in the preclinical studies against many tumors [5]. Because of 
the scarcity of the drug, the difficulties in its isolation, extraction and formulation, a second 
taxane drug, Docetaxel was extracted in 1986 from the needles of the European Yew Taxus 
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 baccata. It is more readily available because of the regenerating capacity of the source and 
slightly better solubility, thus having rapid development than that of paclitaxel [6]. 
Docetaxel differs from paclitaxel in the 10-position on the baccatin ring and in the 3'-position of 
the lateral chain, and has a chemical formula of C43H53NO14 and a molecular weight of 807.9 
(Figure 2.3). It is insoluble in water, but soluble in 0.1 N hydrochloric acid, chloroform, 
dimethylformamide, 95%-96% v/v ethanol, 0.1 N sodium hydroxide and methanol. The 
formulation used in the most recent clinical studies consists of 100% polysorbate 80. 
 
Figure 2.3 Chemical structure of Docetaxel 
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Microtubules are among the most strategic subcellular targets of anticancer agents. Like DNA, 
microtubules are ubiquitous to all eukaryotic cells. They are composed of tubulin dimers 
consisting of an α and a β-subunit protein that polymerize and, with numerous microtubule-
associated proteins (MAPs), decorate the exterior wall of the hollow micro tubule structure [7]. 
There is a continuous dynamic equilibrium between tubulin dimers and microtubules, i.e., a 
continuous balance between polymerization and depolymerization. In addition to being an 
essential component of the mitotic spindle, and required for the maintenance of cell shape, 
microtubules are involved in a wide variety of cellular activities such as cell motility and 
transport between organelles within the cell [8, 9]. Furthermore, they may also have a role in 
modulating the interactions of growth factors with cell-surface receptors and the proliferative 
transmembrane signals produced by these interactions. Many of the unique pharmacologic 
 
 interactions of drugs with microtubules are caused by a dynamic equilibrium between 
microtubules and tubulin dimers [10]. Any disruption of the equilibrium, within the microtubule 
system, would be expected to disrupt the cell division and normal cellular activities in which the 
microtubules are involved. Taxanes bind preferentially and reversibly to the β- subunit of tubulin 
in the microtubules rather than to tubulin dimers. The binding site to tubulin differs from the one 
of vinca-alkaloids and podophyllotoxins. While vincas inhibit polymerization and increase 
microtubule disassembly, the binding of taxanes enhances polymerization of the tubulin into 
stable microtubules and further inhibits microtubule depolymerization, thereby inducing the 
formation of stable microtubule bundles. This disruption of the normal equilibrium ultimately 
leads to cell death. As an inhibitor of microtubule depolymerization, docetaxel is approximately 
twice as potent as paclitaxel. In addition, docetaxel generates tubulin polymers that differ 
structurally from those generated by paclitaxel and does not alter the number of protofilaments in 
the microtubules, while paclitaxel does. 
 
2.4  Docetaxel – A drug with multiple targets 
An anti microtubule agent 
Docetaxel and paclitaxel share a mutual microtubule binding site (for which docetaxel has a 
higher affinity) [11]. There is evidence that they have distinct effects on microtubule dynamics 
[12]. This may underlie the greater potency of docetaxel as a tubulin assembly promoter and 
microtubule stabilizer compared to that of paclitaxel. Furthermore, preliminary data suggest that 
low levels of expression of specific microtubule-associated proteins (e.g., the class II β-tubulin 
isotype) may correlate with higher docetaxel response rates - a potential predictive marker for 
docetaxel activity. The consequences of blocking microtubule dynamics are complex in which a 
number of vital cellular functions in which microtubules play a critical role are compromised. 
Impairment of mitotic progression leading to cell cycle arrest is considered to be a principal 
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 component of docetaxel’s mechanism of action. This blocks progression of a cell through its 
natural division cycle and consequently inhibits cell proliferation. 
 
Docetaxel influences apoptosis pathways 
Disruption of microtubules not only affects progression through the cell cycle, but may also alter 
the signaling pathways involved in processes such as apoptosis. Apoptosis, also known as 
‘programmed cell death’, is a physiologic process involving the activation of certain signaling 
pathways and genetic programs. Defects in this process are believed to contribute to a number of 
human diseases and decreased or inhibited apoptosis is a feature of many malignancies [13]. 
Several studies have demonstrated that docetaxel and other microtubule- targeting agents promote 
apoptosis in cancer cells. Several signal transduction pathways may be involved in docetaxel’s 
effects on apoptosis. The Bcl-2 gene family in particular appears to play a critical role in the 
regulation of apoptosis. Inhibition of Bcl-2 induces apoptosis, whereas over expression of Bcl-2 
prevents or delays apoptosis (enhancing cell survival) and may be a factor relating to 
chemotherapeutic drug resistance. Consequently, down regulation of Bcl-2 expression has been 
investigated as a strategy for reversal of resistance. Anti microtubule agents are believed to cause 
inactivation of Bcl-2 function through phosphorylation [14]. Docetaxel is 10- to 100-fold more 
potent than paclitaxel in phosphorylating Bcl-2 and this may account for the differential pro-
apoptotic activity of docetaxel compared with paclitaxel. An association of docetaxel-induced 
apoptosis with increases in tumor blood vessel diameter may have the beneficial secondary effect 
of improving delivery of other therapeutic agents [15]. 
 
Docetaxel inhibits angiogenesis 
Angiogenesis is the process by which tumors develop new capillary blood vessels. The process is 
vital for tumor progression and is intrinsically connected with metastasis. Furthermore, new 
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 capillaries formed in tumors may be less viable than those in normal tissues and consequently, 
present a barrier for the delivery of chemotherapeutic agents to target cells. Several positive 
endogenous modulators of angiogenesis have been identified, including vascular endothelial 
growth factor (VEGF) and transforming growth factor a (TGF-α), as well as a number of negative 
modulators. Inhibition of angiogenesis is a potential strategy in antitumor drug development, with 
a number of agents currently undergoing clinical investigation [16]. Such a strategy may have 
advantages in relation to toxicity and drug resistance. Docetaxel has been shown to inhibit 
angiogenesis both in vitro and in vivo [17]. The anti angiogenic effect of docetaxel is four times 
stronger than that of paclitaxel [18]. VEGF has been shown to shield tumor cells from the anti 
angiogenic effects of docetaxel and VEGF antibodies can overcome the protective effect both in 
vitro and in vivo. In the clinic, VEGF over expression is associated with larger tumor size, 
increased metastasis, and poor prognosis in metastatic breast cancer (MBC) patients. 
Enhancement of the anti angiogenic properties of docetaxel through inhibition of endogenous 
angiogenic growth factors such as VEGF is a strategy that merits further investigation. 
 
Docetaxel and gene expression 
The taxanes have been shown to be inducers of numerous genes involved in a variety of cellular 
processes [19]. Differences in gene expression may underlie distinctions in the clinical profiles of 
docetaxel and paclitaxel such as the higher incidence of immediate hypersensitivity reactions or 
neurotoxicity associated with paclitaxel. Differences in gene expression may also influence the 
pharmacokinetic characteristics of the taxanes. For instance, unlike docetaxel, paclitaxel activates 
the steroid and xenobiotic receptor (SXR) and consequently induces a number of hepatic enzymes 





 Cellular signaling pathways 
The effect docetaxel has on apoptosis, angiogenesis, and gene expression cannot be considered in 
isolation as these are complex processes involving numerous components. Docetaxel’s ability to 
induce signaling aberrations is likely to trigger numerous messages within tumor cells. 
 
The EGFR pathway 
An example of a signaling pathway that feeds into processes affected by docetaxel, namely 
apoptosis and angiogenesis, is the epidermal growth factor receptor (EGFR) signaling pathway. 
Members of the EGFR family (e.g., the human epidermal growth factor receptors HER-1 and 
HER-2) and their signaling pathways influence cell cycle regulation, angiogenesis, and apoptosis 
[21]. Signals are transmitted from the cell surface to the cell nucleus via a variety of downstream 
effector proteins such as Ras and MAP kinase as shown in Figure 2.4. HER-1 is overexpressed in 
a wide range of tumors, especially squamous cell carcinoma of the head and neck (SCCHN), 
where it is associated with poor prognosis. HER-2 is also overexpressed in many tumor types – in 
particular, breast cancer (30% of tumors). HER-2 overexpression imparts a metastatic advantage 
to the cell and is associated with impaired survival in the patient [22, 23]. There is considerable 





Figure 2.4 EGFR signaling pathway – signals are transmitted from the cell surface to the nucleus via 
effector proteins such as Ras and MAP kinase [24]. 
 
The Ras pathway 
The Ras proteins interact with receptors such as EGFR (as shown in Figure 2.4), cytokines, and 
hormones to play a critical role in intracellular signaling. Ras proteins activate several 
downstream effector pathways that mediate cell proliferation, gene transcription, and apoptosis. 
Tumor cells may harbor Ras mutations or continuously activate the Ras protein to ensure 
downstream effector pathways remain stimulated [25]. Overexpression of Ras has been 
associated with more aggressive types of breast cancer, loss of p53 function and HER-2 
overexpression. For the Ras protein to function it must be anchored to the inner surface of the cell 
membrane. The first step in the anchoring process is the addition of a farnesyl group to Ras – a 
reaction catalyzed by farnesyl transferase (FTPase) enzymes (Figure 2.5). This is a critical step in 
the processing of Ras and inhibition of farnesylation alone may be sufficient to block cell 
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 signaling and cancer cell growth. In this regard farnesyl transferase inhibitors (FTIs) are likely to 
be useful agents in the targeted treatment of tumors expressing wild type Ras protein. 
 
 
Figure 2.5 (a) The first step in Ras modification – the addition of a farnesyl group (FG) – is catalyzed 
by FTPase and enables the protein to localize to the inner surface of the plasma membrane. (b) 
Mechanisms of resistance to docetaxel may be Ras mediated, even if Ras is wildtype in tumors. 
Enhanced G2M arrest by farnesyl transferase inhibitors appears to sensitize cancer cells to taxanes, 
and restore potentially the taxane’s ability to phosphorylate Bcl-2, thereby enhancing the agent’s 
proapoptotic activity [24]. 
 
2.4.1 Limitations of Taxane formulation vehicle 
Toxicity of vehicles 
A high incidence of acute hypersensitivity reactions characterized by respiratory distress, 
hypotension, angioedema, generalized urticaria and rash were observed with paclitaxel 
administration. It is generally felt that cremophor EL contributes significantly to these 
hypersensitivity reactions [26, 27]. These reactions increased with increasing rate of infusion. 
Docetaxel has also known to cause infusion related reactions in the absence of pre medication. 
But these reactions occurred at a decreased frequency when compared with paclitaxel and 
effectively managed by pre medication [28]. Agents formulated with cremophor EL cause 
peripheral neurotoxicity. The oral formulation never induced these adverse side effects. This 
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 shows that cremophor EL is not absorbed through the gastrointestinal tract. Furthermore, 
cremophor EL plasma concentrations achieved after i.v (intravenous) administration have been 
noted to cause axonal swelling, vesicular degeneration and demyelination in rat dorsal root 
ganglion neurons exposed to the formulation vehicle [29]. Recent evidences suggest that 
ethoxylated derivatives of castor oil account for this neuronal damage. Polysorbate 80 is also 
capable of producing vesicular degeneration. Sensory neuropathy has also been associated with 
docetaxel administration but the incidences are much lower when compared with paclitaxel. 
However polysorbate 60 containing epipodophyllotoxin etoposide is not a known neurotoxin, 
suggesting that the mechanism of taxane-induced neuropathy may be multi factorial, atleast in 
part contributed by vehicle formulation [30].  
 
Influence of vehicles of pharmacokinetic on taxanes 
Both cremophor EL and polysorbate 80 have demonstrated to alter the disposition of 
intravenously administered Paclitaxel and Docetaxel. Pharmacokinetic studies conducted in 
mouse models and humans have proved that the non-linear pharmacokinetics of Paclitaxel was 
due to cremophor EL [31, 32]. This altered pharmacokinetics is a resulted of the micellar 
entrapment of paclitaxel by cremophor EL in plasma. It has been shown that the percentage of 
paclitaxel entrapped in micelles increases disproportionately with the administration of higher 
doses of cremophor EL thereby making it less available for the tumor tissue distribution, 
metabolism and biliary excretion[33]. Diminished clearance and prolonged exposure to high 
concentrations of chemotherapeutic agent place patients at higher risk of systemic toxicities. An 
additional problem linked to the cremophor EL solvent is the leaching of plasticizers from 
polyvinylchloride(PVC) bags and infusion sets used routinely in clinical practice. Consequently 
paclitaxel must be prepared and administered in either glass bottles or non-PVC infusion systems 
with in-line filtration. Polysorbate 80 is thought to be rapidly degraded in plasma and does not 
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 interfere with kinetics of docetaxel[34], but recent evidence suggest that this vehicle may 
influence the binding of docetaxel in plasma in concentration-dependent manner[35]. 
 
Impact of vehicles on efficacy of taxane 
Some in vitro models have demonstrated that cremophor EL and polysorbate 8- may enhance 
cytotoxic activity by modulating P-glycoproteins (P-gp) and inhibiting multi drug resistance gene 
expression [36-38]. However this cytotoxic activity was absent in vivo studies due to low volume 
of distribution of cremophor EL and rapid degradation of polysorbate 80 in plasma. Several 
reports suggest that these formulation vehicles may have anti tumor activity on their own. The 
cytotoxic activity of cremophor EL is thought to result from free radical formation by poly 
unsaturated fatty acids and in polysorbate 80, the cytotoxic activity is linked to the release of 
oleic acid, a fatty acid known to interfere with malignant cell proliferation and inhibition of 
angiogenesis[39-41].   
 
2.4.2 Alternative formulations of docetaxel 
Avoiding the use of polysorbate 80 while at the same time developing a drug formulation that 
targets malignant tissue, has received substantial interest recently and has led to several 
alternative, solvent-free docetaxel formulations with varying potential to selectively deliver 
docetaxel to the tumour, thereby potentially enhancing efficacy while decreasing the occurrence 
of undesirable side-effects. 
 
Docetaxel-fibrinogen-coated olive oil droplet 
One approach to avoid polysorbate 80 administration and selectively target the tumour is the use 
of fibrinogen microspheres as delivery vehicle, as previously investigated for other anticancer 
drugs [42, 43]. Local fibrin (ogen) deposition occurs within the stroma of the majority of solid 
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 tumors and is associated with tumor angiogenesis, growth and metastatic potential [44]. In 
addition, thrombin-mediated accumulation and retention of intravenously administered 
fibrinogen-coated olive oil droplets, at fibrin (ogen)-rich sites, has been demonstrated [45]. These 
features initiated the preparation of murine-fibrinogen-coated micronized olive oil droplets loaded 
with docetaxel [46] and subsequently, evaluation of this formulation’s antitumor activity upon 
intraperitoneal (i.p.) administration to mice bearing a fibrin(ogen)-rich ascites tumor [47]. Upon 
i.p. treatment with the docetaxel-fibrinogen-coated olive oil droplet formulation (docetaxel dose 
~20 mg/kg; mean olive oil droplet size ~12 μm), median survival increased approximately 2-fold 
compared to treatment with docetaxel solubilized in polysorbate 80. A preliminary toxicity 
assessment based on the change in weight of healthy, tumor-free mice 15 days following i.p. 
injection of either normal saline, docetaxel solubilized in polysorbate 80 or docetaxel-loaded 
fibrinogen- coated olive oil droplets demonstrated no significant differences. The association of 
docetaxel with tumor cells was monitored by administering tumor-bearing mice either docetaxel 
solubilized in polysorbate 80 or docetaxel-loaded-fibrinogen-coated olive oil droplets, both 
spiked with [3H]-docetaxel. Docetaxel association with tumor cells, measured by liquid 
scintillation counting 48 hours after treatment, was at least 10-fold increased upon i.p. 
administration of docetaxel-loaded olive oil droplets compared to docetaxel solubilized in 
polysorbate 80. These findings suggest potential to improve the therapeutic efficacy of docetaxel 
treatment. However, several issues require to be further addressed, including the feasibility of 
intravenous administration, which requires smaller droplet size, the influence of anticoagulants or 
fibrinolytic agents, which may potentially reduce the therapeutic efficacy of the fibrinogen-coated 
olive oil formulation and toxicity aspects related to the observed significant antibody response 
(i.e. droplet-induced production of anti fibrinogen antibodies), of which the long-term effects on 





Recently, research has increasingly focused on nanotechnological devices for the development of 
(biomarker)-targeted delivery systems for multiple therapeutic agents [49]. Nanotechnology is a 
multidisciplinary field, which covers a diverse array of devices derived from engineering, 
biology, physics and chemistry. These nanotechnology devices (nanotherapeutics) include 
nanovectors aimed at improving the tumor-targeting efficacy of anticancer drugs [47]. An 
injectable drug-delivery nanovector is defined as a hollow or solid structure with a diameter in the 
1 - 1000 nm range. It can be filled with anticancer drugs and targeting moieties can be attached to 
its surface resulting in specific and differential uptake by the targeted cells, in order to deliver a 
constant dose of chemotherapy over an extended period of time. Probably the most well known, 
simplest and earliest examples of nanovectors applied in cancer treatment are liposomes, which 
are a hollow type of nanovector, whereas nanoparticles are considered solid nanovectors. 
Liposomes are spherical particles (vesicles) consisting of one or more lipid bilayer membranes, 
which encapsulate an internal space where notably hydrophilic agents can be entrapped; the lipid 
bilayer membrane of the liposome may serve as a reservoir for hydrophobic drugs. PEGylated 
liposomes (STEALTH® [sterically-stabilized] liposomes) differ from conventional liposomes by a 
polymer (polyethylene glycol, PEG) surface coating. These modified liposomes are characterized 
by reduced uptake by the reticulo-endothelial system, favourable PK (long circulating time, slow 
clearance rate, small volume of distribution), reduced accumulation in healthy tissues and, most 
importantly, by increased, preferential tumor uptake due to their ability to extravasate through the 
hyperpermeable tumor vasculature, a tumor-targeting mechanism known as enhanced permeation 
and retention [50, 51]. These distinct features make PEGylated liposomes an attractive drug 
carrier. Indeed, for anticancer drugs, the advantages of PEGylated liposomes are best illustrated 
by PEGylated liposomal doxorubicin (Caelyx®, Doxil®, Myocet®). The wish to circumvent the 
use of polysorbate 80 and to improve the therapeutic index for docetaxel-based therapy through 
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 specific tumor targeting has led to the successful preparation of PEGylated liposomal docetaxel 
[52] without compromising cytotoxicity. Indeed, in vitro cytotoxic activity of the PEGylated 
docetaxel formulation was almost equipotent to the non-liposomal docetaxel formulation. PK 
profiles for docetaxel solubilized in polysorbate 80 and docetaxel encapsulated in the PEGylated 
liposomes, assessed after a single intravenous bolus dose to mice, were both best described by a 
two-compartment model. However, the PK parameters differed significantly; docetaxel terminal 
half-life was increased nearly 13-fold upon liposomal encapsulation and clearance and volume of 
distribution were decreased more than 100-fold and 6-fold, respectively, compared to docetaxel 
solubilized in polysorbate 80. Further increase of the docetaxel concentration inside the 
PEGylated liposomes (currently 0.7 ± 0.2 mg/mL) is required before initiating clinical trials to 
determine if the improved PK features result in selective and efficient tumor uptake and reduced 
toxicity. Interestingly, in rats and mice [53, 54], the PK of a second dose of PEGylated liposomes 
(devoid of encapsulated drug) was dramatically altered compared to the first dose in a time-
interval dependant manner. The most prominent difference was a major increase in clearance, 
hence the observation is referred to as the ‘accelerated blood clearance’ (ABC)- phenomenon. 
Initially, the ABC-effect was suggested to be caused by a considerable increase in hepatic 
accumulation, possibly involving certain serum factor(s) secreted into the blood after the first 
dose of PEGylated liposomes. Most recently, evaluations have demonstrated that IgM is the 
major serum protein, which selectively binds to PEGylated liposomes upon repeated injection, 
and that these IgM-bound PEGylated liposomes can then activate the complement system [55], 
thus leading to accelerated clearance and enhanced hepatic uptake. Theoretically, the ABC-
phenomenon can potentially compromise therapeutic efficacy and the strongly increased drug 
uptake in the liver may cause severe undesirable liver toxicity. Moreover, repeated administration 
of PEGylated liposomes may lead to the occurrence of unexpected immune reactions. However, 
in clinical practice the occurrence of immune reactions after repeated doses of PEGylated 
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 liposomal doxorubicin is rare (1 - 5 %), suggesting that the observed ABC-phenomenon for 
PEGylated docetaxel may have only a minor impact. Nevertheless, future research in the design 




Covalent attachment of targeting ligands, such as monoclonal antibodies specific for antigens 
expressed on the surface of cancer cells, is another modification of the conventional liposome 
with the aim to improve selective tumor delivery. Docetaxel has been shown to enhance tumor 
response upon irradiation [56], however, clinical application of this radio sensitizing potential is 
limited due to side-effects associated with the drug’s poor tumor selectivity. To increase tumor 
delivery and to evaluate the radio sensitizing properties of docetaxel, human colon 
adenocarcinoma cell lines expressing carcinoembryonic antigen (CEA), were treated with 
irradiation and PEGylated docetaxel ‘immunoliposomes’, i.e. immunoliposomes prepared by 
coupling monoclonal antibodies against CEA to the PEGcoating of the lipid membrane. 
Specifically, cells were incubated (2 h, 37 °C) with different concentrations of immunoliposomal 
docetaxel or liposomal docetaxel (range, 1 - 1000 nmol/L docetaxel) after which the cells were 
washed and further incubated (24 - 48 h, 37 °C). Non-incubated cells received a series of test 
radiation doses ranging from 0 Gy to 8 Gy to determine the degree of radiotoxicity; radiotoxicity 
was most pronounced at a dose of 2 Gy. Consequently, this radiation dose was used to irradiate 
the cells incubated with immunoliposomal- and liposomal docetaxel. Cytotoxicity, assessed using 
the colourimetric MTT assay, was induced by immunoliposomal docetaxel in a dose and time-
dependant manner. Similar evaluation of the cytotoxic efficacy of the multimodality treatment 
demonstrated that the effects of immunoliposomal docetaxel were potentiated upon radiation 
compared to liposomal docetaxel with irradiation or only irradiation. Furthermore, flow 
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 cytometric analysis demonstrated that upon treatment with immunoliposomal docetaxel combined 
with irradiation, apoptosis was significantly increased compared to the multimodality treatment 
for liposomal docetaxel [48]. Further research should determine if this specific immunoliposomal 
docetaxel formulation offers potential to improve local radiotherapy in the treatment of colon 
cancer. 
 
Targeted Docetaxel loaded Nanoparticles 
As mentioned, an expanding number of nanovectors are currently under development for novel, 
optimized drug-delivery modalities. Approaches include molecular targeting of nanovectors 
through conjugation of active recognition moieties to the surface of the nanovector (an approach 
characterized by potential advantages above conventional antibody targeted therapy), intracellular 
targeting of nanoparticles by folate, dendritic polymers as multifunctional nanodevices, silicon 
and silica materials as materials for injectable nanovectors, metal-(e.g. gold) based nanovectors 
and polymer-based nanovectors of which the latter seem to be the most promising for clinical 
translation. Most recently, docetaxel encapsulated nanoparticles formulated with biocompatible 
and biodegradable poly(D,Llactic-co-glycolic acid)-block PEG-copolymer and surface 
functionalized with A10 2’- fluoropyrimidine aptamers (i.e. RNA oligonucleotides; nucleic acid 
ligands) [57] that bind to the extracellular domain of the transmembrane prostate-specific 
membrane antigen (PSMA), a well characterized antigen expressed with high specificity on the 
surface of prostate cancer cells, have been successfully developed in vitro and their cytotoxicity 
evaluated using a xenograft nude mouse prostate cancer model [58]. Due to the surface 
functionalization with the specific PSMA aptamers, these docetaxel-encapsulated nanoparticle-
aptamer bioconjugates (Doc-Np-Apt) exert significantly enhanced cellular cytotoxicity in vitro 
resulting from targeted delivery and enhanced cell-specific uptake compared to non-targeted 
docetaxel-encapsulated nanoparticles (lacking the PSMA aptamer). A single intratumoural 
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 injection of Doc-Np-Apt (40 mg/kg) in vivo was significantly more efficacious regarding tumor 
size reduction and survival time compared to an equivalent dose of non-targeted docetaxel-
encapsulated nanoparticles. The enhanced efficacy was attributed to delayed clearance from the 
target site due to preferential binding to the PSMA proteins, leading to internalization and 
subsequent intracellular drug release. Mean body weight loss at nadir was significantly decreased 
(2-fold) for Doc-Np-Apt compared to non-targeted docetaxel encapsulated nanoparticles, 
suggesting reduced treatment toxicity. Furthermore, there was no evidence of persistent 
hematological toxicity. Several aspects of this approach have the potential to facilitate translation 
into clinical practice, including the fact the poly(D,L-lactide-co- glycolic acid) is a component the 
FDA has approved for clinical use, and the fact that the targeting molecules (aptamers) are small, 
relatively stable, non-immunogenic and easy to produce on a large scale. However, before clinical 
application is possible several aspects, including potential sensitization reactions, 
biological/biophysical barriers impeding targeted delivery and the tailoring of dosing and 
administration schedules remain to be examined. 
 
2.5 Oral Chemotherapy 
2.5.1  Advantages of Oral Chemotherapy 
Oral administration of chemotherapy offers considerable advantages over the parenteral route. 
Greater patient convenience is the biggest advantage. Flexibility for timing and location of 
administration are among the other advantages associated with the use of oral dosage forms. 
Another advantage deals with flexibility of drug exposure. Oral administration of chemotherapy 
can provide more prolonged drug exposure compared with intermittent i.v. infusion, which may 
be important for drugs with schedule-dependent efficacy. Exposure to drug is related to 
exponential factors such as concentration and time. Thus, a drug with a short half-life can achieve 
greater exposure time by either continuous infusion or by continuous oral dosing. This exposure 
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 time can have profound effects on toxicity (e.g., with anti folates) or efficacy (e.g., 
phosphorylation). Another advantage is that the use of oral chemotherapy has the potential to 
reduce the use of healthcare resources for inpatient and ambulatory patient care services (e.g., less 
use of supplies and ancillary support personnel, such as nurses and technicians). Finally, a better 
quality of life may be associated with oral chemotherapy compared with parenteral 
chemotherapy. While oral agents open new vistas for convenience and patient satisfaction, 
several potential problems arise uniquely with the use of oral chemotherapy. Clinicians need to be 
aware of these potential problems and take steps to avoid or minimize them in order to maintain 
the advantages and efficacy of oral agents [59]. 
 
2.5.2  Challenges in Oral Drug Delivery 
Numerous drugs remain poorly available when administered by oral route. Among other reasons, 
this can be due to: (i) low mucosal permeability for the drug, (ii) permeability restricted to a 
region of the gastrointestinal tract, (iii) low or very low solubility of the compound which results 
in low dissolution rate in the mucosal fluids and elimination of a fraction of the drug from the 
alimentary canal prior to absorption, (iv) lack of stability in the gastrointestinal environment, 
resulting in a degradation of the compound prior to its absorption (e.g. peptides, oligonucleotides) 
[60]. 
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In order to circumvent some of these problems, it has been proposed to associate drugs to 
polymeric nanoparticulate systems (or small particles in the micrometre size range). Different 
oral administration experiments in animals have been reported, which have helped to improve the 
pharmacokinetics of several drugs suggesting that the fate of the particles carrying the drug could 
largely influence the absorption of drugs after oral administration. Particles undergoing no 
interactions with the mucosa and direct transit through the gastrointestinal tract represent 
 
 generally an important fraction of the dose administered. In this respect, some of the techniques 
used for macroscopic controlled-release dosage forms allowing an accurate control of the drug 
delivery during the transit can probably be successfully transposed to nanoparticles. As a typical 
example, it has been proposed to trigger the dissolution of nanoparticles and to release the drug at 
specific sites during the transit by using nanoparticles based on pH sensitive polymers [61].  
As an alternative, there have been considerable attempts to lower the particle fraction undergoing 
directly faecal elimination either by increasing the bioadhesive interactions of the particles at the 
surface of the intestinal membrane or their absorption through the membrane itself. When micro- 
or nanoparticles are orally administered in the form of a suspension, they diffuse into the liquid 
medium and they encounter rapidly the mucosal surface during the time-course of their transit in 
the gastrointestinal tract. The particles can be immobilized at the intestinal surface by an adhesion 
mechanism which is referred to as ‘bioadhesion'. More specifically, when adhesion is restricted to 
the mucus layer lining the mucosal surface, the term ‘mucoadhesion' is employed. However, in 
many cases and especially in vivo, the exact localization of the particles at the mucosal surface is 
not precisely known. Because the duration of adhesion is limited, this phenomenon will result in a 
delay in the transit time of the particles in the gastrointestinal tract. 
There has been considerable interest in the concept of bioadhesion since the immobilization of 
drug carrying particles at the mucosal surface would result in (i) a prolonged residence time at the 
site of drug action or absorption, (ii) a localization of the delivery system at a given target site, 
(iii) an increase in the drug concentration gradient due to the intense contact of the particles with 




 The direct contact of particles with intestinal cells through a bioadhesion phase is the first step 
before particle absorption. Historically, the oral absorption pathway has been the subject of in-
depth investigations since the work of Volkheimer [62]. Now it is accepted that particle uptake 
takes place, not only via the M-cells in the Peyer's patches and the isolated follicles of the gut-
associated lymphoid tissues, but also via the normal intestinal enterocytes [63].  
2.5.3 Oral Bioavailability of Docetaxel 
Oral docetaxel treatment would be a convenient way for patients to achieve long-term drug 
exposure. However, development of a suitable oral formulation has been impeded by low (<10%) 
and highly variable oral bioavailability, due to the extensive CYP3A-mediated first-pass 
metabolism and, to a lesser degree, due to affinity for outward-directed transport by ABCB1 in 
the gastrointestinal tract. Modulating these elimination routes has therefore been a focus of 
research. In wild-type mice, exposure to orally administered docetaxel was six-fold lower when 
compared to Abcb1a/1b knockout mice [64]. More importantly, the relative bioavailability 
increased from 4 to 183% by the co administration of the potent CYP3A (and poor ABCB1) 
inhibitor ritonavir, increasing systemic exposure 50-fold. Subsequently, a small PK study, in 
which patients were given oral docetaxel (75 mg/m2) with or without the ABCB1 and CYP3A 
inhibitor CsA, confirmed the observation [65]. In the presence of CsA, systemic exposure 
increased approximately seven-fold (from 0.37 ± 0.33 to 2.71 ± 1.81 mg /h.l). When given 100 
mg/m2 docetaxel i.v. (without CsA), the resulting systemic exposure was 4.27±2.26 mg/ h-1 l-1. 
Adjusted for the difference in dose, exposure following oral administration with concomitant CsA 
does not greatly differ from exposure after i.v. administration without CsA. The investigators 
performed a phase II trial with weekly oral docetaxel (100 mg) in combination with CsA. 
Interpatient PK variability, haematological toxicity and antitumor activity seem to be in the same 
range as for intravenous docetaxel. Oral docetaxel (100 mg) was also combined with OC144-093, 
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 a potent and selective oral ABCB1 inhibitor, and compared to 100mg i.v. docetaxel [66]. The 
relative oral bioavailability of docetaxel was 26 ± 8%, lower than previously observed after CsA 
co administration and systemic exposure after i.v. docetaxel was administered three-fold higher 
compared to the oral application, despite the ABCB1 modulation. This indicating that CYP3A 
mediated (first-pass) metabolism is the crucial process involved in the poor oral bioavailability of 
docetaxel. Notwithstanding the fact that the oral bioavailability of docetaxel can be increased 
through pharmacologic modulation, the development of second-generation oral taxanes is likely 
to prevail [67]. 
2.6 Mucoadhesive nanoparticulate system for Oral drug delivery 
2.6.1 Mucus Structure and Function  
Mucus is a complex viscous adherent secretion which is synthesized by specialized goblet cells. 
These goblet cells are glandular columnar epithelium cells and line all organs that are exposed to 
the external environment. Mucus is found to serve many functions within these locations such as 
lubrication for the passage of objects, maintenance of a hydrated epithelium layer, a barrier 
function with regard to pathogens and noxious substances and as a permeable gel layer allowing 
for the exchange of gases and nutrients to and from underlying epithelium [68]. From an 
engineering point of view, mucus is an outstanding water-based lubricant whose properties are 
extensively exploited within nature. Mucus is composed mainly of water (>95%) and mucins, 
which are glycoproteins of exceptionally high molecular weight (2-14 x 106 g/mol). Also found 
within this viscoelastic soup are proteins, lipids and mucopolysaccharides, which are found in 
smaller proportions (<1%). The mucin glycoproteins form a highly entangled network of 
macromolecules that associate with one another through non-covalent bonds. Such molecular 
association is central to the structure of mucus and is responsible for its rheological properties. 
Furthermore, sialic acid and sulphate groups located on the glycoprotein molecules result in 
28 
 
 mucin behaving as an anionic polyelectrolyte at neutral pH [69]. Other non-mucin components of 
mucus include secretory IgA, lysozyme, lactoferrin, lipids, polysaccharides, and various other 
ionic species. Some of these non-mucin components are believed to be responsible for the 
bacteriostatic action observed in mucus . Obviously, a thorough understanding of the glycoprotein 
mucin component is very important with regard to understanding the properties of mucus. Mucin 
glycoproteins may be described as consisting of a basic unit made from a single-chain 
polypeptide backbone with two distinct regions:  
(1) A heavily glycosylated central protein core to which many large carbohydrate side chains are 
attached, predominantly via O-glycosidic linkages. 
(2) One or two terminal peptide regions where there is little glycosylation. These regions are 
often referred to as ‘naked proteins regions’. 
 




 Mucin is stored in both submucosal and goblet cells, wherein the negative charges of the mucin 
glycoprotein are shielded by calcium ions, which allows for the compact packing of such 
molecules. During release into luminal space, out flux of calcium exposes these negative charges 
resulting in electrostatic repulsion and an approximate 400-fold expansion of the molecule. These 
elongated mucin chains entangle and form non-covalent interactions such as hydrogen, 
electrostatic, and hydrophobic bonds leading to the development of a viscoelastic gel [71]. In the 
presence of water, these mucin chains begin to overlap, interpenetrate and form a structured 
network that mechanically functions as mucus. The overall rheological behaviour of mucus is a 
result of flow resistance exerted by individual chain segments, physical chain entanglement and 
non-covalent intermolecular interactions [72]. The exact composition of mucus may vary with the 
site of secretion, its physiological or mechanical role, and the presence of any underlying disease 
state. One particular point of interest is the strategic position of mucus in many disease processes 
in which the interactions of epithelial cells and their surroundings have gone astray such as is 
seen in inflammatory and infectious diseases, cancer and metastasis [73]. Such scenarios may 
allow a means of targeting therapeutics to such conditions more effectively. 
2.6.2 Theories of Mucoadhesion 
Mucoadhesion is a complex process and numerous theories have been presented to explain the 
mechanisms involved. These theories include mechanical-interlocking, electrostatic, diffusion-
interpenetration, adsorption and fracture processes, surface energy thermodynamics and 
interpenetration/diffusion. These theories should be considered as supplementary processes 
involved in the different stages of the mucus/substrate interaction, rather than individual and 
alternative theories [74]. 
 The wettability theory 
The wettability theory is mainly applicable to liquid or low viscosity mucoadhesive systems and 
is essentially a measure of the ‘‘spreadability” of the active pharmaceutical ingredient delivery 
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 system across the biological substrate. This theory postulates that the adhesive component 
penetrates surface irregularities, hardens and anchors itself to the surface. The adhesive 
performance of such elastoviscous liquids may be defined using wettability, spreadability and 
critical parameters that can be determined from solid surface contact angle measurements. This 
process defines the energy required to counter the surface tension at the interface between the two 
materials allowing for a good mucoadhesive spreading and coverage of the biological substrate. 
Mucoadhesive polymer systems that exhibit similar structure and functional groupings to the 
mucus layer will show increased miscibility which in turn will result in a greater degree of 
polymer spreadability across the mucosal surface. In Lower water, the polymer contact angles of 
such systems will facilitate hydration of the polymer chains and thus promote intimate contact 
between polymeric delivery platform and the mucus substrate. However, in the case of an 
extremely hydrophilic polymer, the water contact angle will be much lower than that of the 
mucosal surface, thus discouraging such an intimate contact due to a high interfacial surface free 
energy [75]. 
 
The electronic theory 
This theory describes adhesion occurring by means of electron transfer between the mucus and 
the mucoadhesive system arising through differences in their electronic structures. The electron 
transfer between the mucus and the mucoadhesive results in the formation of a double layer of 
electrical charges at the mucus and mucoadhesive interface. The net result of such a process is the 
formation of attractive forces within this double layer [76].  
 
The fracture theory 
According to this theory, the adhesive bond between systems is related to the force required to 
separate both surfaces from one another. This ‘‘fracture theory” relates the force for polymer 
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 detachment from the mucus to the strength of their adhesive bond. The work fracture has been 
found to be greater, when the polymer network strands are longer or if the degree of cross-linking 
within such as system is reduced [77]. This theory allows the determination of fracture strength 
(r) following the separation of two surfaces via its relationship to Young’s modulus of elasticity 
(E), the fracture energy (e) and the critical crack length (L) through the following equation[78]: 
 
 
The adsorption theory 
In this instance, adhesion is defined as being the result of various surface interactions (primary 
and secondary bonding) between the adhesive polymer and mucus substrate. Primary bonds due 
to chemisorption result in adhesion due to ionic, covalent and metallic bonding, which is 
generally undesirable due to their permanency. Secondary bonds arise mainly due to van der 
Waals forces, hydrophobic interactions and hydrogen bonding. These interactions require less 
energy to break and they are the most prominent form of surface interaction in mucoadhesion 
processes as they have the advantage of being semi-permanent bonds [78]. 
 
The diffusion-interlocking theory  
This theory proposes the time-dependent diffusion of mucoadhesive polymer chains into the 
glycoprotein chain network of the mucus layer. This is a two-way diffusion process with 
penetration rate being dependent upon the diffusion coefficients of both interacting polymers. 
Although there are many factors involved in such processes, the fundamental properties that 
significantly influence this inter-movement are molecular weight, cross-linking density, chain 
mobility/flexibility and expansion capacity of both networks [79]. Furthermore, temperature also 
has been noted as important environmental factor for this process [80]. It is acknowledged that 
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 longer polymer chains may diffuse, interpenetrate and ultimately entangle to a greater extent with 
surface mucus but, it should be recognised that a critical chain length of at least 100,000 Da is 
necessary to obtain interpenetration and molecular entanglement. Additionally excessive chain 
cross-linking will act to decrease the polymer mobility and thus interfacial penetration. Another 
significant contributory factor in determining interpenetration is the miscibility of both systems 
with one another. It is reasonable to postulate then that maximum diffusion and bioadhesive 
strength may be achieved when the solubility parameters of the bioadhesive polymer and the 
mucus glycoprotein are similar [81].  
 
2.6.3 Factors affecting Mucoadhesion 
With reference to the theories of mucoadhesion, various polymer structural and functional 
groupings can have an effect on the likelihood and degree of polymer/mucus interaction. As such 
the potential for the modification or control of such polymer properties may allow for specific 
tailoring of mucoadhesive delivery systems. 
 
Functional group contribution 
The attachment and bonding of bioadhesive polymers to biological substrates occurs mainly 
through interpenetration followed by secondary non-covalent bonding between substrates. 
Mucoadhesive polymers possessing hydrophilic functional groups such as, carboxyl (COOH), 
hydroxyl (OH), amide (NH2) and sulphate groups (SO4H) may be more favorable in formulating 
targeted drug delivery systems. Typically, physical entanglements and secondary interactions 
(hydrogen bonds) contribute to the formation of a strengthened network and therefore polymers 
that exhibit a high density of available hydrogen bonding groups would be able to interact more 
strongly with mucin glycoproteins[74]. Mucoadhesive polymers are generally hydrophilic 
networks that contain numerous polar functional groups. Consequently, such functionalized 
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 polymers interact with the mucus not only through physical entanglements but also through 
secondary chemical bonds, thus resulting in the formation of weakly cross-linked networks [69]. 
The key sites for mucoadhesive interactions appear to be on the carbohydrate residues, via 
electrostatic interaction or through hydrophobic bonding of fucose clusters[82]. The significance 
of hydrogen bonding within mucoadhesion processes has been recently reported by Hagesaether 
and Sande [83]. 
 
Degree of hydration 
Another important factor affecting the mucoadhesive strength of polymeric components is the 
degree of hydration. Some polymers exhibit adhesive property when the amount of water is 
limited. Under such conditions, adhesion is the result of a combination of capillary attraction and 
osmotic forces between the dry polymer and the wet mucosal surface which act to dehydrate and 
strengthen the mucus layer [84]. Whilst hydration is essential for the relaxation and 
interpenetration of polymer chains, excess hydration could lead to decreased mucoadhesion 
and/or retention due to the formation of slippery mucilage. In this situation cross-linked polymers 
that permit only a certain degree of hydration may be advantageous for providing a prolonged 
mucoadhesive effect. 
 
Polymer molecular weight, chain length, conformation, and degree of cross-linking 
It is well accepted that structural polymeric components significantly influence the extent of 
diffusion, entanglement and hence mucoadhesion. A large molecular weight is essential for 
entanglement. However, excessively long polymer chains lose their ability to diffuse and 
interpenetrate mucosal surfaces [85]. Research within this field has shown that each polymeric 
system is unique preventing the definition of an optimum molecular weight. Dextrans, for 
example, with molecular weights of 19,500,000 and 200,000 possess similar bioadhesive strength 
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 which may be explained in terms of the helical conformation resulting in shielding of potential 
bioadhesive sites inside coiled conformers at higher molecular weights. Conversely poly(acrylic) 
acid has an optimal MW of about 750,000, whereas polyethylene oxide has an optimum MW 
closer to 4,000,000. Whilst a critical length is necessary to produce bioadhesive interactions, 
additionally the size and shape of the interpenetrating polymeric chains must be considered. The 
degree of cross-linking within a polymer system significantly influences chain mobility and 
resistance to dissolution. Cross-linked hydrophilic polymers swell in the presence of water 
allowing them to retain their structure, whereas similar high molecular weight linear hydrophilic 
polymers are swellable and readily dispersible. In mucoadhesive terms, swelling is favorable as it 
not only allows greater control of drug release, but also the swelling process increases the surface 
area for polymer/mucus interpenetration. As cross-link density increases, chain mobility 
decreases and hence the effective chain length, which can penetrate into the mucus layer, 
decreases, reducing mucoadhesive strength [86]. Chain flexibility is critical for interpenetration 
and entanglement with the mucus gel. Increased chain mobility leads to increased inter-diffusion 
and interpenetration of the polymer within the mucus network. 
 
pH and charge 
The charge density of macromolecules is an important factor for bioadhesion with polyanions 
preferred to polycations when considering both toxicity and bioadhesion [87]. Macromolecular 
charge is affected by the pH of the physiological environment due to the dissociation of 
functional groups. Undoubtedly, there is a greatest potential for polymer mucus hydrogen 
bonding with undissociated anionic pendant functional groups. In relation to carboxylated 
polymers, pH values below the respective pKa value would then be more favorable [88]. An 
article published almost 20 years ago by Park and Robinson [89] suggests that approximately 
80% protonation of carboxyl groups is necessary for mucoadhesion within polyacrylic acid 
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 systems. Whilst it is recognized that mucoadhesion processes are optimized in low pH 
environments, mucoadhesion may not be completely lost at higher pH values. At higher pH 
levels, the repulsion of ‘‘like” COO-  functional groups changes the spatial conformation from a 
coiled state into a ‘‘rod-like” structure, making them more readily available for inter-diffusion 
and interpenetration. Interestingly, above the pKa of mucin, a net negative charge may result in 
the repulsion of anionic species such as observed in ionized polyacrylic acid systems. At such 
elevated pH values, positively charged polymers, such as chitosan, may form polyelectrolyte 
complexes with negatively charged mucins and exhibit strong mucoadhesion [90]. Mucoadhesive 
polymers may be divided into three main groups in terms of overall charge, i.e., anionic, cationic 
and non-ionic systems. Anionic polymer systems such as the polyacrylic acids make up the bulk 
of pharmaceutically employed mucoadhesive polymers. The effect of polymer charge on 
mucoadhesion has been clearly demonstrated by Bernkop-Schnürch and Freudl [91]. In this work, 
various chemical entities were attached to chitosan and the mucoadhesiveness of the resulting 
charged polymer was assessed. Cationic chitosan HCl showed marked adhesiveness when 
compared to the control (a force of detachment of 32.4 ± 14.5 mN compared to 1.3 ± 0.1 mN). 
The attachment of ethylene diamine tetra acetic acid (EDTA), an anionic functional group, 
significantly increased mucoadhesive strength (81.7 ± 9.9 mN). Interestingly the addition of 
diethylene triamine penta acetic acid (DTPA) resulted in a system exhibiting both anionic and 
cationic characters. Such a phenomenon resulted from a lower binding affinity of DTPA when 
compared to that of EDTA possibly arising from steric hindrance. Mucoadhesive testing showed 
that the DTPA/chitosan system exhibited significantly lower mucoadhesive strength (3.0 ± 1.3 
mN) in comparison to the cationic chitosan and anionic EDTA/chitosan complexes. This 
difference was attributed to the reduction in overall charge density that would have been expected 




 Polymer concentration 
Polymer concentration has also been shown to significantly influence the strength of 
mucoadhesion. Optimal polymer concentration is dependent on physical state of the delivery 
system, with observational differences between semisolid and solid-state platforms. In the 
semisolid state, an optimum concentration exists for each polymer beyond which reduced 
adhesion occurs because a lower number of polymer chains are available for interpenetration with 
mucus. On the other hand, solid dosage forms such as buccal tablets exhibit increased adhesive 
strength as the mucoadhesive polymer concentration increases [92]. 
 
Environmental and physiological factors 
There are numerous environmental and physiological factors that will have a marked effect on the 
mucoadhesive strength of polymer systems. Most of these factors such as pH and the amount of 
fluid at the biologically targeted area have been discussed previously. One significant factor not 
mentioned so far is the variable mucus turnover at the applied surface/site throughout the body. 
Undoubtedly, the most critical aspect is the time required to replenish the mucus layer. Such a 
shedding process is paramount in the body’s fight against pathogens and will eventually lead to 
the shedding and excretion of even the most adhesive drug delivery systems. The maximum 
duration in which a mucoadhesive system may adhere to the mucosal tissue will therefore be 
limited by the turnover time of the mucus gel layer. For some mucosal tissues, where mucus 
turnover is relatively low (e.g. mouth or vagina), this may be of less critical importance. 
However, in areas of markedly high mucus turnover such as in the intestines, adherence time is 
probably not longer than a couple of hours [93]. Mucus gel layer viscosity can vary throughout 
the body, with variability increasing in certain disease states. Low mucus viscosity results in a 
weak, easily detachable polymer/mucus bond, making targeted drug delivery extremely difficult. 
In contrast an extremely viscous mucus layer, such as those thickened due to white blood cell 
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 DNA, dead cells and inflammatory mediators limits the degree of interpenetration and also 
increases the diffusion pathway through which the active agent must pass [19,32]. Furthermore, 
the ionic strength of the surrounding medium may also have a significant role in defining the 
mucoadhesive bond force. In general, mucoadhesion strength is decreased in the presence of ions 
due to shielding of functional sites that are pertinent for adhesion processes and importantly, gel 
network expansion [94, 95]. It is worth to note that this generalization is not always applicable, 
and indeed certain polymer systems such as gellan are dependent upon the presence of divalent 
cations for in situ gelation [96]. 
2.6.4.  Engineering particles to cross mucus barriers 
 
2.6.4.1 Role of surface chemistry 
Polystyrene nanoparticles as small as 59 nm, covalently modified with carboxyl groups on the 
surface, were found to be completely immobilized in human cervical mucus [97]. By reducing the 
concentration, Dawson et al. found that some particles with surfaces modified with either 
carboxyl or amine groups were mobile in CF sputum, but the ensemble-averaged transport rates 
were still slowed at least 300-fold compared to the same particles in water [98]. Norris et al. 
similarly observed slow transport of nanoparticles surface-modified with carboxyl, sulfate, or 
amidine groups, although the fastest transport was found with the most hydrophilic (amidine) 
surface [90]. In contrast, Sakuma et al. studied the in vivo behavior of nanoparticles having 
surface poly(N-isopropyl acrylamide), poly(N-vinylacetamide), poly(vinylamine), or 
poly(methacrylic acid) chains, and observed increased mucoadhesion for all chains except for 
poly(N-vinyl acetamide) [99, 100]. The increased mucoadhesion by the various hydrophilic 
chains was attributed to the presence of tertiary amines which may interact with anionic 
components of mucus. Thus, no clear correlation existed between the surface chemistry of 




 2.6.4.2 Coating particles with low molecular weight polyethylene glycol 
A faithful mimic of the muco-inert viruses would involve developing synthetic particles with a 
similarly high density of both cationic and anionic surface charge groups. However, although 
techniques have been advanced to generate multiple alternating layers of oppositely charged 
coatings with thicknesses on the order of angstroms [101], the engineering of such densely 
charged, yet, neutral coatings onto the surfaces of synthetic particles remains exceedingly 
difficult. Furthermore, even if such chemistry is possible and scalable, densely charged synthetic 
particles may exhibit immunogenicity similar to viruses. To circumvent the difficult chemistry 
and immunological concerns, we abstracted the features of the highly charged, yet, net neutral 
surfaces of viruses to encompass high hydrophilicity and neutral charge. In particular, instead of a 
high density of charge groups, we hypothesized an uncharged surface may be as muco-inert as 
viral capsids, provided the surface is sufficiently hydrophilic and low H bonding. We thus 
screened through GRAS (generally regarded as safe) polymers that may satisfy the dual 
requirements namely (i) strong hydrophilicity and (ii) neutrally charged. Polyethylene glycol 
(PEG) is an uncharged hydrophilic polymer routinely used in pharmaceutics to improve systemic 
circulation and minimize opsonization [102]. However, it was not obvious, a priori, that PEG 
may reduce association of particles with mucus, since PEG was widely used as a mucoadhesive 
agent [85, 103]. Some authors have reported that PEG chains may establish adhesive interactions 
due to their ability to inter-diffuse with the mucus network [102-104] and undergo hydrogen 
bonding. It should be noted that a large fraction of the early work depicting PEG as 
mucoadhesive was based on PEG coating of hydrogel systems, where the characteristic size of 
the gel is far greater than the average mucus pore spacing. A number of reports over the past 
decade have further suggested PEG to enhance the mucoadhesive properties of nanoparticles , 
although the density of the PEG coating was typically poorly characterized. In light of these 
findings, we hypothesized that coating particles with a high density of PEG may reduce particle-
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 mucus adhesive interactions, provided  (i) the M.W. of PEG was too low to support adhesion via 
polymer interpenetration and (ii) the PEG density is sufficient to effectively shield the 
hydrophobic core common to many biodegradable polymers. The hypothesis was tested by 
covalently modifying the surfaces of polystyrene nanoparticles with a high density of low M.W. 
(2 kDa) PEG, and studied their diffusion in fresh undiluted human mucus . Contrary to reports of 
PEG being mucoadhesive, a dense PEG coating, as characterized by a near-neutral surface charge 
and negligible protein adsorption, improved the transport of nanoparticles by up to 3 orders of 
magnitude for particles in the range of 100-500 nm in size . Large nanoparticles (200 and 500 nm 
in diameter) densely coated with PEG diffused through mucus with an effective diffusion 
coefficient (Deff) only 6- and 4-fold lower than that for the same particles in water. The greatly 
improved nanoparticle transport rates upon PEGylation correlated with a sharp decrease in the 
fraction of immobile particles for all sizes tested. Less than 0.5% of 200 and 500 nm PEGylated 
particles were immobilized by mucus compared to 32 and 45% for uncoated 200 and 500 nm 
particles, respectively. To our knowledge, this is the first report to demonstrate that synthetically 
engineered nanoparticles can rapidly penetrate fresh undiluted human mucus barriers. Despite the 
marked improvement of nanoparticle transport upon PEG modification, a significant fraction of 
100 nm PEG-modified particles were found to be immobile or strongly hindered in mucus [105]. 
One possible explanation for the slower transport of 100 nm (vs. 200 and 500 nm) particles may 
be inadequate PEGylation of 100 nm particles. It was found that a 40% lower surface coverage of 
2 kDa PEG, compared to particles well coated with 2 kDa PEG, caused a 700-fold decrease in the 
average transport rate. Particles similarly well coated with 5 kDa PEG diffused as rapidly through 
mucus as those with 2 kDa PEG, but a further increase of PEG M.W. to 10 kDa resulted in 1000-
fold slower transport. These results suggest that both dense surface coverage and low M.W. PEG 
are required for PEG-coated particles to rapidly penetrate mucus. Using this design principle, 100 
nm particles that can rapidly penetrate mucus were designed (unpublished observations). By 
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 comparing our results to previously published studies of the interaction of PEG-coated particles 
with mucus, we estimated the range of PEG M.W. and particle surface charge (an indirect 
measure of PEG surface coverage on non-neutral core particles) that likely provides muco-inert 
PEG coatings (Figure 10) [106]. 
In addition to improving transport, PEGylation of nanoparticles may also enhance their stability 
in mucus. Stability is particularly important when particles must diffuse through a thick mucus 
layer in order to reach underlying cells. Various studies have demonstrated that liposomes are not 
stable in the GI tract, particularly in the presence of bile salts [107]. Low gene transfer to lung 
epithelia by lipoplexes administered via intratracheal or intranasal instillation has been attributed 
to the low stability and substantial aggregation of liposomes in mucus. Upon PEGylation, Sanders 
et al. found that mucus components did not interact significantly with PEG-GL67 lipoplexes, and 
prior exposure to the mucus components did not reduce their gene transfer. Similarly, in vitro 
incubation of PEG coated polylactide nanoparticles in simulated gastric fluid demonstrated 9-fold 
higher chemical stability than polylactide particles alone [108].  
 
2.6.4.3 Implications of large “mucus penetrating” particles 
Much to our surprise, we were able to engineer 200 and 500 nm particles to rapidly traverse fresh 
human cervicovaginal mucus. This directly implies that the average effective mesh spacing in 
human cervicovaginal secretions must be significantly larger than earlier reports [105] and must 
include a large number of pores with effective spacing substantially larger than 500 nm. It is 
unlikely that the rapid transport of PEGylated particles is due to alterations of the mucus 
structure, because they do not interact significantly with mucus. Instead, particles likely move in 
low-viscosity channels or pores within the mucus, as suggested in our earlier work on particle 
transport in cystic fibrosis mucus [98]. Furthermore, since our results are obtained with fresh, 
undiluted cervicovaginal mucus that is rheologically and compositionally comparable to mucus 
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 found in the airways of the lungs and gastrointestinal tract [105]. It is possible that large 
PEGylated nanoparticles may also transport quickly in mucus coating other entry sites into the 
body. In cases of less hydrated mucus, diffusion rates of nanoparticles may not differ markedly 
from those found in fresh cervicovaginal mucus, since the inter fiber spacing does not strongly 
depend on hydration. The rapid mucosal transport of large (200 and 500 nm) PEG-modified 
particles has important implications for the development of therapeutic and imaging applications 
in vivo. Larger nanoparticles afford substantially higher drug encapsulation as well as reduced 
aggregation upon freeze drying. In addition, as the size of drug-loaded particles increases, the 
drug-release kinetics are usually greatly improved as well, allowing sustained release of 
therapeutics over days and even months along with enhanced therapeutic efficacy. In contrast, 
smaller nanoparticles suffer from large burst release typically within hours upon in vitro or in 
vivo application [109, 110]. These findings should strongly encourage the commercial 
development of new nanoparticle-based drug delivery systems for applications at mucosal 
surfaces. Although large nanoparticles are preferred for improved drug loading and release 
kinetics, an optimal size likely exists for mucosal applications. Nanoparticles that are too large, 
even if they are well coated so as to avoid mucoadhesion, may not diffuse at rates sufficient for 
overcoming mucociliary clearance due to the elevated friction forces predicted by the Stokes-
Einstein equation. Since mucus layer thickness and mucus clearance time differ among the 
mucosal tissues, different nanoparticle diffusion rates may be required in order to overcome 
different mucus barriers. Furthermore, for cellular uptake into underlying epithelia, an increase in 
particle diameter is expected to reduce the rate of endocytosis. The size of mucus penetrating 
particles must be optimized with all of these considerations, and will likely vary based on the 





 2.6.4.4. Disrupting the mucus barrier to enhance particle transport 
Treatment of mucus with mucolytic agents [111] may improve the penetration rates of drug and 
Gene carrier particles. The use of mucolytics as an adjuvant to particle transport may be 
particularly important for diseases, where mucus is abnormally viscoelastic, such as cystic 
fibrosis and chronic obstruction pulmonary disease (COPD). For example, in CF sputum, water 
content is reduced and cellular debris is increased, leading to an increase in physical 
entanglements, a decrease in the average mesh pore spacing, and a pronounced increase in the 
viscoelastic nature of the sputum . Consequently, CF mucus is suggested to be a confounding 
barrier even to viruses [112], as well as a major cause for low gene transfer efficiencies in vivo. 
Pulmozyme®, a recombinant human DNase (rhDNase) also known as Dornase alfa, is the most 
commonly used mucolytic in CF and a potential candidate as an adjuvant to particle transport. 
Pulmozyme hydrolyzes the DNA that forms dense entanglements with mucin glycoproteins and 
other mucus constituents, thus reducing the number of crosslinks and the viscoelasticity of mucus 
[113, 114]. However, in a diffusion chamber study, Sanders et al. found only a moderate 
improvement in the transport of uncoated polystyrene nanospheres through CF sputum treated 
with rhDNase [115]. Dawson et al. observed that, while rhDNase treatment of undiluted CF 
sputum reduced its macro viscoelastic properties by up to 50%, it did not improve particle 
diffusion rates. Multiple particle tracking analysis revealed that rhDNase treatment dramatically 
narrowed the distribution of individual particle diffusion rates in CF sputum, effectively 
removing the fast-moving “outlier” particle population. Dawson et al. suggested that soluble 
DNA fragments created by DNase treatment may increase the micro viscosity within mucus 
pores, thereby eliminated fast-moving particles. This finding suggests that rhDNase may reduce, 
rather than enhance, the efficacy of nanoparticle therapeutics such as non-viral polymeric gene 
vectors, since the treatment eliminates the fast-moving fraction that may be critical for effective 
CF gene therapy [111]. Mucinex® (N-acetyl-L-cysteine; NAC) is another common mucolytic 
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 previously tested for its ability to improve the penetration of nanoparticles across CF sputum. 
NAC reduces the cross-linking of mucin fibers by cleaving disulfide bonds and thus the bulk 
mucus rheology. Alton and coworkers showed that the mucus barrier to non-viral gene vectors 
may be at least partially overcome by treatment with NAC in an ex vivo model of sheep tracheal 
epithelium [116].  NAC treatment has also been shown to increase reporter gene expression in the 
mouse lung. However, no correction of the nasal transepithelial potential difference was observed 
in CF-null mice, suggesting NAC alone may be inadequate to induce clinically relevant gene 
therapy via mucoadhesive cationic liposomes and polymers. Although not widely investigated, 
other promising mucolytic agents are well established for reducing the bulk rheological properties 
of mucus and may potentially improve nanoparticle transport through mucus. The varying effects 
of mucolytics, as in the cases of NAC and rhDNase,suggest that any potential adjuvant use of 
mucolytics must be carefully investigated for each agent. Furthermore, patients may respond 
differently to various mucolytics. A more thorough understanding of failures in mucolytic 
response in different patients may alleviate these concerns [117]. 
 
2.6.5 Montmorillonite 
The usage of clay minerals for curative and protective purpose is as old as mankind itself [118]. 
The local or generalized application of thermal muds called peloids has been done in terms of 
pelotherapy to recover rheumatism, arthritis, and bone-muscle traumatic damages Medicinal clays 
have been widely used in medicine and properly administered  clays can purify the blood, reduce 
or even eliminate infection, heal ulcers, and even rid the body of certain allergies.  Cutaneous 
chemotherapy based on clay minerals for the treatments of seborrhoeic skin as antimicrobial and 
antifungal agents has also been developed. Nowadays, the importance of cellular delivery of 
various drugs and bio-active molecules in medicine leads to advanced development in novel area 
of chemistry,biology and  material sciences. Studies on both natural and synthetic clay minerals 
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 including layered double hydroxides(LDHs) for biological applications are extensively carried 
out [119]. 
Montmorillonite which is classified into 2:l type dioctahedral smectites has received 
comparatively large attention because of its good swelling property and high exchange capacity 
[1,2]. Montmorillonite has a net negative charge on the layer surface owing to the isomorphic 
substitution, which is naturally balanced by exchangeable inorganic cations, such as Na+ and Ca2+, 
which are in general hydrated in the presence of water. The hydration of exchangeable cations 
and the polar nature of surface silanol (Si-O) groups impart a hydrophilic nature to the 
montmorillonite surface. As a result, water is preferentially taken up by these surfaces and non-
polar organic molecules cannot compete with the strongly bound water on the adsorption sites of 
the clay surface[120]. As the metal ions are replaced by large surfactant cations, such as long 
chain alkylammonium ions, the nature of the clay surface is drastically modified. While the 
natural clays are in general hydrophilic, the surfactant-modified clays (organoclays) are 
hydrophobic or organophilic in nature [121] 
 
2.6.5.1 Mechanisms of clay–drug interactions 
Ion exchange process 
Clay minerals are naturally occurring inorganic cationic exchangers and so they may undergo ion 
exchange with basic drugs in solution. Smectites, especially montmorillonite and saponite, have 
been the more commonly studied because of their higher cation exchange capacity compared to 
other pharmaceutical silicates (such as talc, kaolin and fibrous clay minerals). Nevertheless, there 
are several mechanisms that may be involved in the interaction between clay minerals and 
organic molecules. The relevance of a specific mechanism depends on the clay mineral involved) 




 The interaction between montmorillonite and four alkaloids was investigated and some 
differences in bonding mechanisms depending on molecule size and basicity were determined. In 
some cases (methapyrilene and triethylamine) drug molecules were quantitatively bound to the 
clay mineral via cation exchange; besides ion exchange other mechanisms contributed to drug 
adsorption of larger molecules (brucine); and niacinamide was not bounded to the clay, because it 
mainly occurred in the neutral form. It was confirmed that basic molecules bonded strongly to 
montmorillonite; on the other hand, complexes with anionic and non-ionic drugs exhibited much 
weaker interaction bonds and more rapid desorption kinetics. [122] 
 
Adsorption and Ion–dipole Interactions 
Bonding via adsorption [123] and ion–dipole interactions [124] of acidic and non-ionised 
molecules with montmorillonite were previously reported. The crucial effect of the ionisation 
degree of drug molecules on their interaction with smectites was then corroborated using 
dioctahedral smectite as the adsorbent substrate. Besides smectites, other silicates were 
investigated to vehicle bioactive compounds. Fibrous clay minerals (attapulgite) and magnesium 
trisilicate (sepiolite) and kaolinite in particular were considered because of their large surface area 
and/or widespread pharmaceutical application. Adsorption studies of benzoic acid and 
crystalviolet on kaolin suggested that anionic species (benzoicacid) were adsorbed on the edge 
faces of the mineral, and cationic (crystal violet) on the basal plane surfaces [125]. The 
adsorption isotherms of some β-blockers (including propranolol, acebutolol, metoprolol, nadolol, 
oxprenolol) and mebeverine [126] with fibrous clay minerals and kaolinite were investigated, at 
different pH and temperature. Several studies aimed to improve understanding of the physical–
chemical aspects of drug–clay complexes. X-ray diffraction was a useful tool to test the 
penetration and possible orientation of cationic drugs in the interlayer space of smectites, by 
revealing changes in the basal spacing of the clay minerals. Spectroscopic (UV–VIS, IR) and 
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 thermal (TGA) analyses were also successfully used to reveal cation as well as chemical bonds to 
active sites of the clay minerals and changes in the spectral characteristics or in the acid-base 
equilibria of drug molecules used X-ray diffraction and FT-IR analysis to study desorption of 
cationic drugs differing in molecular size from loaded montmorillonite.  
Other studies focused on clarifying the role of some key parameters (e.g., drug concentration, pH, 
temperature, electrolyte concentration and valence, dielectric constant) in drug-clay adsorption-
desorption processes. On the basis of these interactions, but also because of their special swelling 
properties, clay minerals are effectively used to delay (extended-release systems) and/ or target 
(site-specific release systems) drug release or even improve drug solubility. Finally, new 
strategies are focused on increasing drug stability and simultaneously modifying drug delivery 
patterns (particulate delivery systems) (Table 2.2 ). 
Table 2.2 New Drug delivery systems based on clay materials 
Issue Target parameter Delivery system Mechanism Excipients Original clay 
Release 
Pattern 







































































 Toxicity assessment  
To know the detailed toxic and/or inhibitory phenomena of MMT, both pathological and 
toxicological analyses were adopted as indicator methods. Wistar rats were administered by oral 
and intravenous injection with high dose of MMT as an in vivo animal model to examine acute 
toxicological effects of MMT in 72 hour basis. The data obtained from various hematological and 
blood-biochemical analyses were evaluated by significant test in Biostatistics. Pathological (e.g., 
hematological and blood biochemicalanalysis) upon physiological conditions in Wistar rats 
appeared no apparent difference between the groups administered with MMT and phosphate 
buffered saline (PBS). Histopathological sections of rat organs also confirmed the promising 
potential of MMT in a clinical application. In addition, a generally considered safe and non-
pathological microorganism, Saccharomyces cerevisiae, was selected as a model microorganism 
(i.e., baker s yeast) for comparative study. The standard dose-response assessment  also suggested 
that the presence of MMT in composite solutions only slightly inhibited growth of S. cerevisiae. 
All models of toxicity assessment evidently suggested that MMT is non-toxic and safe for 
myriads of applications [127]. 
 
2.6.6 VITAMIN E –TPGS 
D-α-tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS or TPGS) was developed 
in the 1950s as a water-soluble derivative of lipid-soluble natural vitamin E, which is prepared by 
esterification of D-α-tocopheryl succinate (TOS) with polyethylene glycol 1000. TPGS appears a 
waxy solid at room temperature and stable in air. The molecular weight is around 1542 Da. TPGS 
possesses a very low critical micelle concentration (CMC) that is 0.02% and can form low 
viscosity solutions in water until the concentration at 20 wt%, beyond which lipid crystalline 
phases may form [128]. TPGS is an amphiphile consisting of lipophilic alkyl tail and 
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 hydrophilic polar head portion (PEG), which results in the bulky structure and large 
surface area. The hydrophile-lipophile balance (HLB) of TPGS is about 13.2. The unique 
chemical properties of TPGS have suggested its application as a solubilizer, an 
emulsifier, an absorption enhancer, a plasticizer, a water-soluble source of vitamin E, and 
a carrier of hydrophobic drugs. TPGS shows no human toxicity data to date.  
 
Solubilizer for Water-insoluble Compounds  
It is well known that quite a few drugs, especially anticancer drugs, are poorly water soluble. 
There are many strategies improving solubility and TPGS is a powerful tool to solubilize many 
hydrophobic agents. TPGS was used as solubilizing adjuvant to formulate emulsion of an oily 
composition of several antitumor drugs [129]. Another early step on the solubilizing effect of 
TPGS is the work by Ismailos et al.[130]. The aqueous solubility of cyclosporine A (CyA) at 
three different temperatures (5, 20 and 37 °C) showed 2- to 16-fold increase in the presence of 
various concentrations of TPGS ranging from 0.01 to 0.05 mM. Later, Yu, L. et al [131] reported 
that TPGS significantly improved solubility of the poorly water soluble drug amprenavir, which 
is a potent HIV protease inhibitor. The solubility linearly increased with increasing TPGS 
concentration through micelle solubilization since no increase showed when the concentration of 
TPGS was below CMC. TPGS was also found enhancing the solubility of another selective HIV-
1 non-nucleoside reverse transcriptase inhibitor, thiocarboxanilide UC-781. Moreover, a dramatic 
increase in estradiol solubility was found in the aqueous solvent as well as in various 
concentration of ethanol with TPGS. Recently, a new successful story was documented involving 
anticancer drug paclitaxel [132]. Aqueous solubility of paclitaxel was significantly enhanced up 





 Absorption Enhancer  
TPGS has caused much attention on its ability to enhance the absorption of several drugs that, 
otherwise, have poor bioavailability. TPGS could enhance absorption of the lipophilic drug 
cyclosporine, which is an immunosuppressive agent to prevent the rejection of transplanted 
organs. As a consequence, the required daily dosage of cyclosporine was significantly reduced to 
maintain therapeutic blood plasma concentration of the drug. TPGS also displayed well as an 
absorption enhancer in amprenavir [132], which has been already used in commercial amprenavir 
capsules, an agenerase that contains approximately 36 IU of vitamin E in 50 mg capsule. Besides 
many examples of TPGS used for poorly water soluble drugs, examples of TPGS used in poorly 
permeable drugs that are water soluble were also reported.  
 
Bioavailability Enhancer  
As a water-soluble derivative of natural vitamin E, TPGS alone or TPGS/d-α-tocopheryl acetate 
blend provides enhanced bioavailability in not only animals but also some populations of human. 
Quite a few studies supported the use of TPGS to deliver vitamin E in human exhibiting fat 
malabsorption [133]. The vitamin E trial was performed using an emulsified form of tocopheryl 
acetate, showing the concentrations of tocopherols in plasma, erythrocytes and adipose tissues 
after administration were high with TPGS. Thus TPGS provided better bioavailability than the 
other forms. The proposed mechanism explained that the formed TPGS micelles could cross from 
the intestinal lumen to enterocytes. TPGS may be hydrolyzed to release the tocopherol which 
may be transferred into the enterocyte or the whole TPGS micelle could be taken up by the 
enterocyte. Besides, TPGS can also improve the bioavailability of other fat soluble vitamins, such 
as vitamin D [134].  Not only can TPGS improve the bioavailability of vitamins, it also can 
enhance the bioavailability of pharmacological compounds halofantrine, cyclosporine A, 
paclitaxel [132, 135, 136]. TPGS can play a role as reversal agent of P-gp mediated 
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 multidrug resistance (MDR) and inhibit P-gp substrate drugs transporting. For example, 
TPGS significantly increased the bioavailability of P-gp substrate talinolol in 
coadministration with talinolol form in vitro cell permeability on Caco-2 cells and in vivo 
intraduodenal perfusion study [137]. Moreover, TPGS was found to enhance the 
cytotoxicity of doxorubicin, vinblastine, paclitaxel and colchine that are P-gp substrate 
agents in G185 cells but not for that of 5-FU which is not P-gp substrate. TPGS can 
improve the permeability of a drug across cell membranes by inhibiting P-gp, and thus 
enhance the bioavailability and absorption of a drug. 
 
Drug Delivery Applications  
Polymeric drug carriers, by which the drug can be entrapped, encapsulated, adsorbed, attached or 
coupled, open a new era of drug delivery to provide sustained, controlled and targeted effects. In 
drug delivery, TPGS can be used to improve the dissolution rate and bioavailability by forming a 
solid dispersion or a solid solution, controlling or modifying the release of the drug, and masking 
the bitter taste of a drug. Due to the bulky amphiphilic structure and large surface area, TPGS is 
expected to act as a good emulsifier or surfactant in drug delivery system, especially in 
fabricating micro/nanoparticles. TPGS can be a good surfactant in oral delivery of protein drugs 
and in synthesis of biodegradable magnetic microspheres. TPGS can also be surfactant coating 
material in fabrication of PLGA nanoparticles by modified solvent extraction/evaporation 
method. Mu and Feng demonstrated that TPGS acted as a more effective and safer emulsifier for 
fabrication and characterization of polymeric nanoparticles in comparison with traditional PVA 
[138]. TPGS can achieve far higher emulsification efficiency with the amount of 0.015% (w/w) in 
fabrication whereas 1% PVA is required in similar process. Co-polymerizing TPGS with a 
polymer such as PLA, PLGA or PCL can enhance the emulsification efficiency and drug loading 
51 
 
 capability as demonstrated in the studies on microencapsulated paclitaxel [139]. The in vitro drug 
release was increased by 2-fold after one day and 3-fold after 31 days for the PLGA and 
PLA/TPGS nanoparticles, respectively. It also showed to tailor the release rate via increasing the 
entrapped drug release. Besides, TPGS can be used as a good additive in fabricating PLGA 
nanoparticles and discs for paclitaxel formulation with up to 80% drug loading efficiency. The 
further in vitro and in vivo investigation confirmed the great potential of TPGS in drug delivery. 
Feng et al. demonstrated that TPGS emulsified nanoparticles could increase cancer cell mortality 
and enhance the cellular uptake of Caco-2 cells that used as a model of the GI barrier. 
Nanoparticles coated by TPGS eliminated the acute side effects caused by Cremophor EL which 
is an adjuvant in commercial Taxol. In in vivo PK investigation of PLA-TPGS nanoparticles 
prepared by the dialysis method, 1.8-times larger AUC and 11.6-times longer half-life were 
observed than that of Taxol after i.v. administration. As it is for TPGS emulsified PLGA 
nanoparticles, 4.9-times increased AUC and 2.4-times prolonged therapeutic time in comparison 
of Taxol after i.v injection were reported. Moreover, TPGS displayed promise as a matrix 
material in nasal delivery. Prepared by the combination of double emulsion method and spray 
drying method, diphtheria taxoid loaded PCL/TPGS microspheres exhibited high immune 
response than that achieved using PCL microspheres alone, which showed favorable potential of 










 CHAPTER 3. MATERIALS AND METHODS 
 
3.1 Materials: 
Docetaxel of purity 99.56% was purchased from Shanghai Jinhe Bio-Technology Co. Ltd, China. 
Sodium MMT (Closite Na+) was provided by Southern Clay Products Incorporated, USA. 
Vitamin E TPGS (D-α-tocopheryl polyethylene glycol 1000 succinate, C33O5H54 (CH2CH2O)23) 
was from Eastman chemical company (USA). Lactide (3,6-dimethyl-1,4-dioxane-2,5-dione), 
PLGA (L:G molar ratio: 50:50; MW: 40,000-75,000), polyvinyl alcohol (PVA) (MW: 30,000-
70,000), phosphate buffered saline (PBS), Dulbecco’s Modified Eagle Medium (DMEM), 
trypsin-EDTA and thiazolyl blue tetrazolium bromide (MTT) were obtained from Sigma. 
Dichloromethane (DCM), acetonitrile, methanol, ethanol and ethyl acetate, all of HPLC grade, 
were purchased from Tedia Company Incorporated. Penicillin-streptomycin and Hank’s Balanced 
Salt Solution (HBSS) were provided by Invitrogen Corporation. Coumarin 6 was obtained from 
Aldrich. Fetal bovine serum (FBS) was purchased from HyClone. Sodium hydroxide was 
provided by Merck. Triton X-100 was obtained from USB Corporation. Isopropanol was 
purchased from Kanto Kagaku Singapore Private Ltd. Heparin was provided by Mayne Pharma 
Private Ltd. Ultra-pure deionized water (Millipore, Bedford, MA, USA) was used throughout this 
study. All other chemicals used were of reagent grade and were used as received. 
3.2        Methods 
3.2.1     Synthesis of PLA-TPGS copolymer 
PLA-TPGS copolymers were synthesized by ring-opening bulk polymerization of lactide 
monomer with vitamin E TPGS in presence of stannous octoate as catalyst [139]. In brief, 
weighted amounts of lactide, TPGS and 0.5 wt% stannous octoate (in distilled toluene) were 
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 added in a flask. Lactide was recrytallized twice before the experiment to remove any impurities. 
TPGS was kept in freeze drier for two days before the reaction to remove any residual water 
molecules. The reaction vessel was also kept dry and purged with nitrogen before adding the 
reactants. The mixture was heated to 145 °C and allowed to react for 12 h. All synthesis were 
carried out under an oxygen- and moisture- free environment. The product was dissolved in DCM 
and then precipitated in excess cold methanol to remove unreacted lactide monomers and TPGS. 
The final product was collected by filtration and vacuum dried at 45 °C for two days. The TPGS 
content and number-averaged molecular weight of the copolymer was determined by 1H NMR in 
CDCl3 at 500 Hz (Bruker AMX500). The weight-averaged molecular weight and molecular 
weight distribution was determined by gel permeation chromatography (GPC, Waters GPC 
analysis system with RI-G1362A refractive index detector) using THF (tetrahydrofuran) as the 
solvent and polystyrene standards. 
3.2.2 Synthesis of PLA-TPGS nanoparticles emulsified with TPGS /MMT 
Docetaxel-loaded PLA-TPGS nanoparticles were fabricated by a modified solvent 
extraction/evaporation method [138]. In short, a given amount of docetaxel and 100 mg PLA-
TPGS or PLGA were dissolved in 8 ml DCM. The formed solution was poured into 120 ml 
aqueous solution containing 0.03% w/v TPGS and various amounts of MMT (0 and 0.046%, 
w/v). The mixture was sonicated for 120 s at 20 W. The emulsion was then stirred overnight on 
magnetic stirrer to remove the organic solvent. The particle suspension was centrifuged at 11,000 
rpm for 20 min and then washed three times to remove the unloaded drug and surfactant. The 
resulted particles were resuspended in 10 ml water and freeze-dried for two days. The fluorescent 
coumarin-6 loaded PLA-TPGS NPs were prepared in the same way except 0.05% (w/v) 




 3.2.3 Characterization of nanoparticles 
3.2.3.1 Size and Surface charge 
The particle size and size distribution of the prepared nanoparticles were measured by laser light 
scattering. The dried powder samples were suspended in deionised water and slightly sonicated 
before measurement. The obtained homogenous suspension was determined for the volume mean 
diameter, size distribution and polydispersity. The sample was diluted several times so that the 
particle count does not exceed 1 Mcps. Zetapotential is a measure of the charge on the surface of 
the nanoparticles. zetapotential was measured by a zeta potential analyser (Zeta Plus, Brookhaven 
Instruments). The freeze dried particles were similarly suspended in deinoised water. 
3.2.3.2 Surface morphology 
The shape and surface morphology of the produced nanoparticles were investigated by Field 
Emission Scanning Microscope (FESEM) and Atomic force Microscope (AFM, Multimode 
Scanning Probe Microscope). A drop of the nanoparticle suspension was dried on the carbon tape 
and was then coated with platinum using a Auto fine coater(Jeol, JFC-1300) for 30 s at 30mA. 
The stubs were then loaded into the FESEM instrument. For AFM, the nanoparticle suspension 
was dried on a glass slide and the particles were seen under the microscope in tapping mode. 
 
3.2.3.3 MMT content analysis 
MMT content in the fabricated NPs were estimated by Thermogravimetric analysis(TA 2050, TA 
Instruments). MMT clay particles were delaminated in water by magnetic stirring at 500rpm for 
24 hours and then were freeze dried for 2 days for TGA analysis. 5mg of a freeze-dried, 
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 docetaxel-loaded NP samples or MMT was placed in an alumina crucible and heated from 25°C 
to 670°C at 20°C/min under a nitrogen gas flow of 20ml/min. 
3.2.3.4 Drug Encapsulation efficiency calculations 
Docetaxel content in the fabricated NPs were determined as follows. 3mg of a freeze-dried, 
docetaxel-loaded NP sample was dissolved in 3ml of DCM. The DCM was allowed to evaporate 
under room conditions and the deposited paclitaxel was subsequently dissolved in 5ml of a HPLC 
mobile phase containing 50% water and 50% acetonitrile. The resulting solution was analyzed by 
HPLC (Agilent LC 1100, Agilent Technologies, Singapore) using a reverse phase ZORBAX 
Eclipse XDB-C18 column (250×4.6mm i.d., pore size 5mμ, Agilent Technologies, Singapore) 
with a mobile phase containing of 50% water and 50% acetonitrile at a flow rate of 1ml/min. 
Docetaxel was detected using a variable wavelength detector at a wavelength of 230nm. Finally, 
docetaxel content in the sample was calculated using a standard docetaxel concentration 
calibration curve, which was linear over concentrations ranging from 10-100,000ng/ml with a 
correlation coefficient of R2 = 0.999. For each sample, this docetaxel quantification process was 
performed 3 times and the docetaxel content of each sample was taken as the average of the 3 
measurements. The EE of each sample was calculated as the ratio of the amount of docetaxel 
present in the final product to the total amount of docetaxel used during formulation. Extraction 
efficiency of this docetaxel quantification process was determined by dissolving a fixed amount 
of docetaxel with blank PLGA, PLGA-MMT , PLA-TPGS and PLA-TPGS/MMT NPs 
performing the docetaxel extraction and quantification as described and calculated as the amount 
of docetaxel obtained from the measurement process to the original amount of docetaxel added to 
the blank NPs. An extraction efficiency of 100% was obtained, implying that all the docetaxel in 
a sample could be extracted and detected. As such, no correction was needed for the EE values 
obtained using this quantification process. 
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 3.2.3.5 Physical status of Docetaxel and MMT in nanoparticles 
The physical status of docetaxel inside the nanoparticles was characterized by differential 
scanning calorimetry thermogram analysis( DSC, 2920 Modulated, Universal V2.6D TA 
instruments). 8mg of the sample were sealed in standard aluminium pans with lids. The samples 
were purged with pure dry nitrogen at a flow rate of 40 ml/min. A temperature ramp speed was 
set at 10°C/min and the heat flow was recorded from 25 - 250°C. Indium was used as standard 
reference material to caliberate the temperature and energy scales of the DSC instrument. DSC 
analysis of pure docetaxel and all the four nanoparticle formulations were carried out to identify 
the melting point peak.  
The physical status of MMT was analyzed using X-Ray Diffraction (LabX-XRD6000, Shimadzu 
Corporation). For XRD analysis, freeze-dried, docetaxel-loaded NP samples or MMT was placed 
on an aluminum sample holder and the diffraction angle (2θ) of the sample was recorded from 5° 
to 45° at a scan speed of 2°/min using CuKα radiation as the X-ray source at 40kV and 30mA. 
3.2.3.6 In vitro drug release study 
The dialysis method was applied to monitor the release of docetaxel from the nanoparticles in the 
presence of 0.1% Tween80. 10 mg of nanoparticles were suspended in 5ml of (10mM) PBS at 
pH7.4 with 0.1% Tween80 in a dialysis bag (molecular cutoff of 8000Da) and were incubated in 
15ml of PBS (0.1% Tween80, pH7.4) at 37°C under horizontal shaking at 120rpm. At 
predetermined time intervals 5ml aliquots of the release medium was removed and the same 
volume of fresh solution was added. Tween80 was added to the release medium to improve the 
solubility of docetaxel and prevent any precipitation in the release medium. The amount of 
docetaxel released at each time point was determined by the HPLC as described above for 
encapsulation efficiency determination. 
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 3.2.4 In vitro cellular studies 
3.2.4.1 In vitro Cell Uptake Efficiency 
Caco-2 cells of passages 59-63 (American Type Culture Collection) were used in this study to 
simulate the GIB in oral chemotherapy. The cells were grown in 75cm2 tissue culture flasks and 
maintained in a humidified atmosphere with 5% CO2 at 37°C. DMEM supplemented with 10% 
FBS, 100U/ml penicillin and 100μg/ml streptomycin was used as the culture medium and 
changed every 2 days. When the cells reached 90% confluence, they were collected by 0.25% 
trypsin-EDTA solution and seeded into black 96-well plates (Corning Incorporated) at a density 
of 105cells/well for quantitative cell uptake study. NP suspensions at different particle 
concentrations (100, 250 and 500μg/ml) were prepared by dispersing freeze-dried, Coumarin 6-
loaded PLGA, PLGA-MMT, PLA-TPGS and PLA-TPGS/MMT NPs in DMEM. When the cells 
in the black 96-well plates reached 90% confluence, the DMEM was removed and after 
incubation with 100μl of HBSS per well for 1 hour, the cells were incubated with 100μl of NP 
suspensions per well at various particle concentrations for 2 hours. After incubation, the NP 
suspensions were removed and the cells were washed thrice with 100μl of PBS per well per wash. 
Subsequently, 100μl of DMEM and 50μl of 0.5% Triton X-100/0.2M NaOH were added to each 
well to solubilize the cells. Finally, fluorescence intensity of each well was measured using a 
microplate reader (SAFIRE II, TECAN Austria GmbH) at excitation and emission wavelengths 
of 420nm and 505nm respectively. For each sample, 2 columns i.e. 16 wells, were used. The first 
column was kept intact after incubation as the positive control and its fluorescence intensity (IP) 
represented the total amount of NPs added. The second column was used as samples for 
investigation and its fluorescence intensity (IS) represented the amount of NPs taken up by the 
cells. The fluorescence intensity of the cells alone (IN) was used as the negative control and it 
58 
 
 represented the background fluorescence intensity. Cell uptake efficiency of Coumarin 6-loaded 
NPs was expressed as follows:  
Cell Uptake Efficiency = ( IS - IN )/( IP - IN ) X 100 
Cell culture of MCF-7 cells (American Type Culture Collection) and their uptake efficiency for 
Coumarin 6-loaded NPs were carried out likewise for comparative studies. 
3.2.4.2 Confocal Imaging of cancer cells 
PLA-TPGS/MMT NP suspensions at a particle concentration of 250μg/ml were prepared in 
DMEM. Caco-2 and MCF-7 cells were seeded into glass chambers (Lab-Tek® Chambered 
Coverglass System) and cultured as described previously in Section 3.2.4.1. After 48 hours, the 
DMEM was removed and after incubation with 1ml of HBSS per well for 1 hour, the cells were 
incubated for 2 hours with 500μl of NP suspension. Subsequently, the NP suspension was 
removed and the cells were washed thrice with 1ml of PBS per well per wash. The cells were 
then fixed with 1ml of ethanol per well for 20 minutes and washed thrice again with 1ml of PBS 
per well per wash after removal of the ethanol. Next, the cells were incubated with 1ml of 
propidium iodide solution per well for 45 minutes to stain the cell nuclei. Finally, after removal of 
the propidium iodide solution and washing the cells thrice again with 1ml of PBS per well per 
wash, the cells were covered with 400μl of PBS per well and observed using CLSM (Olympus 
IX70, Olympus America, Inc) with a FITC filter. 
3.2.4.3 In vitro Cytotoxicity of Nanoparticles 
MCF-7 cells were seeded into transparent 96-well plates (NUNC) at a density of 105 cells/well 
and cultured as described previously in Section 3.2.4.1. After 24 hours, the DMEM was removed 
and the cells were incubated with 100μl per well of NP suspensions or Taxotere® solution in 
DMEM at different docetaxel concentrations ranging from 0.025-25 μg/ml. At specific time 
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 intervals (24, 48 and 72 hours), the DMEM/NP suspensions/Taxotere® solution were removed 
and the cells were washed thrice with 100μl of PBS per well per wash. Cytotoxicity was 
determined by MTT assay and the absorbance reading in each well was measured with a micro-
plate reader (SAFIRE II, TECAN Austria GmbH) at a wavelength of 570nm and a reference 
wavelength of 620 nm. A total 8 wells were used for each sample and wells without any drug 
treatment were used as controls. Cell viability was expressed as the ratio of the absorbance 
reading from the sample wells to that of the control wells. From the cell viability percentage at 
different concentrations, IC50 (concentration at which 50% cells are killed) was calculated for 
different formulations at different time intervals. 
3.2.5 In vivo pharmacokinetic study 
Male Sprague-Dawley (SD) rats of 150-200 gm and 4-5 week old were supplied by the 
Laboratory Animals Centre of Singapore and were maintained at the Animal Holding Unit of 
National University of Singapore. The animal caring and handling and the protocols were 
approved by the Institutional Animal Care and Use Committee (IACUC), Office of Life Science, 
National University of Singapore. The animals were acclimatized at temperature of 25 ± 2 ºC and 
relative humidity of 50-60 % under natural light/dark conditions for one week before 
experiments. The animals were randomly distributed into six groups. Group 1 received an i.v. 
injection of Taxotere® (n=5).  Group 2, 3, 4, 5 and 6 received an oral delivery of taxotere,  
docetaxel-loaded PLGA NPs, PLGA/MMT NPs, PLA-TPGS NPs and PLA-TPGS/MMT NPs 
(n=6) respectively. The docetaxel-loaded nanoparticles and Taxotere® were dispersed or diluted 
with saline and administered at the same docetaxel dose of 10 mg/kg body weight. All animals 
were observed for their general condition, clinical signs, and mortality. For Group 1 and 2, blood 
samples were collected at 0 (predose), 0.5, 1, 2, 5, 8, 12, and 24 hrs. For Group 3 and 4, blood 
samples were collected at 0 (pre-dose), 0.5, 1, 2, 5, 8, 12, 24, 48, 72, 120, 168, 217, 336, 410 and 
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 480 hr after administration of the drug. Plasma samples were harvested by centrifugation at 
11,000 rpm for 10 min and stored at -20°C for HPLC analysis. Docetaxel in the plasma samples 
was extracted into 1 ml of diethyl ether and was allowed to evaporate in separate tubes. 100 μl of 
HPLC mobile phase A (acetonitrile/methanol/water = 45/5/50 v/v/v) was added to the dried tubes 
and centrifuged at 10500rpm for 15min. 90 μl of the supernatant was transferred to HPLC vial 
inserts and 50 μl was injected into the column. An elution gradient was applied by increasing the 
proportion of A from 0 to 100% in 50 min and then the system was brought to initial condition of 
100% B (acetonitrile/methanol/water = 40/5/50 v/v/v)  and equilibrated for 5 min by holding at 
100%B. The flow rate was 1ml/min and the total run time was 55min. The docetaxel 
concentration in plasma was determined using the standard curve obtained for known 
concentrations of docetaxel in plasma processed similarly. The curve was found to be linear in the 
















 CHAPTER 4. RESULTS AND DISCUSSIONS 
 
4.1 Characterization of PLA-TPGS copolymer  
PLA-TPGS copolymer of ratio 89:11 was synthesized in this research and was further used for 
the synthesis of drug loaded nanoparticles. The characterization of 1H NMR and GPC were 
tabulated in Table 4.1. Figure 4.1 shows the characteristic NMR spectroscopy of the PLA-TPGS 
copolymer. The signals at 5.2 and 1.69ppm correspond to –CH protons and methyl protons -CH3 
of PLA segment respectively. The peak at 3.65 correspond to –CH2 protons of the PEO part of 
TPGS. The peak areas at 5.2 and 3.65 were used to calculate the number averaged molecular 
weight (Mn) of the copolymer[139, 140]. 
PLA-TPGS copolymer (89:11) of this specific ratio was purposefully used in this research. 
Previous work in our group have studied the drug release kinetics and cellular uptake of NPs 
synthesized from PLA-TPGS copolymers of varying ratio. From these studies it can be observed 
that higher TPGS content in the copolymer can lead to a rapid release rate of the encapsulated 
drug which not desired in the case of oral administration and lower TPGS content will also lead 
to lower uptake of NPs from the intestine [140]. Thus it was concluded that PLA-TPGS (89:11) 
copolymer is best suited for the synthesis of nanoparticles to be administered orally. 







PI(Mw/ Mn)  Mw  Mn
PLA‐TPGS 
89:11 
15.0  11.05  1.62  18,926  11,683





Figure 4.1 1H-NMR spectra of PLA-TPGS copolymer in CDCl3 
 
4.2 Characterization of drug-loaded NPs 
4.2.1 Size, zeta potential, MMT content, and drug encapsulation efficiency 
The size of the drug-loaded NPs prepared in this research is shown in Table 4.2. The size of the 
nanoparticle is a key parameter determining its uptake from the intestine. The permeability of the 
particle through the intestinal mucosa decreases with increasing particle size reaching a cut-off at 
500nm [141, 142]. The synthesized nanoparticles were 200-300nm in size favoring the intestinal 
uptake of the nanoparticles. 
It can be observed that the addition of MMT slightly increased the size of the nanoparticle. But at 
the same time it also increased the negative zeta potential on the particle surface, which favored 
the uptake as well the stability of the particles in solution. Studies also showed that particle with 
higher negative surface charge are more attracted to the mucosal surface thus preventing 
elimination through the alimentary canal [141]. Moreover MMT is a bioadhesive clay and hence 
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 it adheres to the mucus of the gastrointestinal tract preventing the elimination through the 
alimentary canal.  











PLGA 293.2 0.172 -32.7± 3.11 0 69.3% 
PLGA  332.6 0.173 -38.3±7.82 23.47% 60.23% 
PLA-TPGS 201.4 0.121 -29.02± 1.94 0 83.4% 




Figure 4.2 Thermogravimetric analysis curves of freeze-dried MMT and docetaxel-loaded NPs 
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 The content of MMT in the docetaxel-loaded PLGA/MMT and PLA-TPGS/MMT NPs was 
estimated by TGA by neglecting the encapsulated drug due to its minor fraction. Figure 4.2 
shows the TGA traces of freeze-dried MMT, PLGA NPs, PLGA/MMT NPs, PLA-TPGS NPs and 
PLA-TPGS/MMT NPs. From 20 to 600oC, the pure PLGA and PLA-TPGS NPs exhibited about 
96% weight loss. In comparison, only 10 % weight loss was observed for freeze-dried MMT in 
the same temperature range. Therefore, the weight loss of PLGA/MMT (75%) and PLA-
TPGS/MMT NPs (72.66%) in this heating range can be reasonably attributed to the pure PLGA 
and PLA-TPGS NPs respectively. Thus, the content of MMT in PLGA/MMT and PLA-
TPGS/MMT NPs was determined to be around 25 % in both NPs. 
The drug encapsulation efficiency was found to be higher in PLA-TPGS nanoparticles compared 
to PLGA nanoparticles. This is because of the self emulsifying efficiency of PLA-TPGS 
copolymer together with TPGS as emulsifier. The presence of MMT does not significantly affect 
the encapsulation efficiency. NPs with high drug encapsulation efficiency are essential during 
preclinical animal studies since it will reduce the amount of nanoparticles to be administered for a 
given dose. 
4.2.2 Surface morphology 
  The drug-loaded NPs were found by FESEM to be spherical in shape and their size also 
confirmed the LLS results (Figure 4.3). It can also be found from the image that both of PLGA 
NPs and PLA-TPGS NPs with and without MMT exhibit smooth surface within the FESEM 


















Figure 4.4 AFM images of Docetaxel – loaded Nanoparticles 
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 4.2.3 Physical status of docetaxel and MMT in the nanoparticles 
  Physical status of docetaxel in the nanoparticles was investigated by DSC (Figure 4.5). The 
melting endothermic peak of pure docetaxel appeared at 173°C. However, no melting peak was 
detected for all four NP formulations. It can thus be concluded that docetaxel in the NP 
formulation was in an amorphous or disordered crystalline phase or in the solid solution state. 
The XRD spectrum of MMT and docetaxel-loaded NPs is shown in Figure 4.6. The 
disappearance of the characteristic peak (2θ = 5.8º) of MMT in NPs suggested that MMT was 
amorphously distributed in the nanoparticles.  
 
 




Figure 4.6 XRD of MMT and doceatxel-loaded PLA-TPGS/MMT NPs 
 
4.2.4 In vitro drug release 
  The in vitro drug release profiles of the docetaxel-loaded NPs in the first 28 days are shown in 
Figure.4.7. The initial burst of 17.7%, 21.5%, 22.6% and 28.6% in the first 5 days can be 
observed for PLGA/MMT NPs, PLA-TPGS/MMT NPs, PLGA NPs and PLA-TPGS NPs 
respectively, which is followed by an approximately first –order release afterwards. The results 
further confirmed the previous findings that PLGA NPs showed significantly slower release than 
PLA-TPGS NPs [140]. The presence of MMT on PLA-TPGS and PLGA NPs slightly reduced 
the release rate of the drug. This may be because of the slower degradation of the polymer in the 
presence of MMT and partially because of the adsorption of the drug to MMT. This shows that 
major portion of docetaxel remain encapsulated in the nanoparticles and are taken up into the 
cells as nanoparticles and not as free drug. The cumulative release at the end 28 days was 40.7, 
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 38.03, 28.4 and 26.6 % for PLA-TPGS, PLGA, PLA-TPGS/MMT and PLGA/MMT NPs 
respectively. The sustained release can be explained due to slow erosion and degradation of the 
polymer together with the drug diffusion. Though the in vitro release has not been performed 
under conditions simulating in vivo, this study gave an idea of the relative rate of degradation and 
drug release from different nanoparticulate system. 
 
Figure 4.7 In vitro drug release profile of drug-loaded NPs 
 
4.3 In vitro cellular Studies  
4.3.1 Uptake of courmarin 6-loaded nanoparticles by Caco-2 and MCF-7 cells 
Nanoparticles in the gut lumen are either (i) degraded, (ii) absorbed from the intestine or (iii) 
eliminated. Caco2 cell monolayers form a useful model to predict the absorption of the orally 
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 administered drug, since many brush border enzymes and transport proteins are functional in 
caco2 cells [143, 144]. The cellular uptake of PLGA, PLGA/MMT, PLA-TPGS and PLA-
TPGS/MMT nanoparticles have been compared in Caco2 and MCF7 cell lines. Taxanes have 
been extensively used to treat metastatic breast cancer [145]. The cell uptake in MCF7 cells 
provided a useful data to predict the therapeutic effect of the nanoparticles in breast cancer. The 
cellular uptake efficiency of the fluorescent coumarin 6-loaded NPs by Caco-2 and MCF-7 cells 
was assayed upon 2h incubation and the results are shown in Figure 4.8A and 4.8B respectively. 
The cellular uptake efficiency of PLA-TPGS NPs was 1.52, 1.65, and 1.55-fold higher than 
that of PLGA NPs at the incubated particle concentration of 100, 250, and 500 μg/ml, 
respectively. For PLA-TPGS/MMT NPs, the cellular uptake efficiency was 1.76, 2.22, and 2.59-
fold higher than the PLGA NPs, respectively. In addition, the cellular uptake efficiency of PLA-
TPGS/MMT NPs was 1.16, 1.34, and 1.67-fold higher respectively as compared with PLA-TPGS 
NPs. The cellular uptake of PLGA/MMT NPs was comparable to that of PLA-TPGS NPs which 
can be attributed to the presence of MMT and TPGS on the surface of the NPs. As shown in 
Figure 4.8B, the cellular uptake efficiency of NPs by MCF-7 cells was also dose-dependent. At 
particle concentration of 100 μg/ml, all four NP formulations have almost the same degree of 
cellular uptake. However, the cellular uptake efficiency of PLA-TPGS NPs was 1.24-, and 1.21-
fold higher than that of PLGA NPs at the incubated concentration of 250 and 500 μg/ml, 
respectively. For PLA-TPGS/MMT NPs, the cellular uptake efficiency was 1.42-, and 1.98-fold 
higher than the PLGA NPs, respectively. Furthermore, PLA-TPGS/MMT NPs have 1.14- and 
1.64-fold higher level of cellular uptake respectively when compared with PLA-TPGS NPs.  
The uptake efficiency was found to be proportional to particle concentration and incubation 
time. It can be clearly observed that PLA-TPGS/MMT nanoparticles have the highest uptake 
followed by PLA-TPGS nanoparticles. The difference in the uptake efficiency was more 
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 pronounced at higher particle concentration in both the cell lines. PLA-TPGS nanoparticles have 
shown higher cellular uptake than PLGA nanoparticles in HT29 cells [146]. Similar results were 
observed in Caco2 cell lines also. The higher uptake of PLA-TPGS nanoparticles was because of 
higher TPGS concentration on the particle surface compared to TPGS emulsified PLGA 
nanoparticle [147, 148]. 
The above results also show that incorporation of MMT in the NP formulation can 
significantly enhance the interactions between NPs and cells. The enhanced interaction may be 
partly due to the increased viscosity of the particle suspension, which may help the NPs to 
associate with cells/mucus. In addition, MMT may develop London-van der Waals forces and 
hydrogen bonding with the cells. Suspended together with MMT, the NPs were surrounded 
and/or adsorbed by MMT, which acted as adhesives between the particles and the cells. Hydrogen 
bonding may be formed between the hydroxyl groups of glycol proteins and the water of 
hydration of the cations on the clay. The developed London-van der Waals forces and hydrogen 
bonding may be mainly responsible for the increased particles-cells interactions. Further polymer 
MMT nanocomposites have also been used as substrates for fibroblasts cells which demonstrated 
a positive interaction between the cells and MMT [149]. 
4.3.2 Confocal laser scanning microscopy 
  Figure 4.9 & 4.10 show the Confocal Laser Scanning Microscopy (CLSM) images of Caco-2 
and MCF-7 cells after 2 hours incubation with coumarin 6-loaded PLA-TPGS/MMT NPs at 250 
μg/ml NP concentration, in which, the left image was obtained from FITC channel (green), the 
middle one was from propidium iodide (PI) channel (red), and the right one was obtained from 
combined PI channel and FITC channel. In the cell cytoplasm, around the red nucleus (PI stained) 
are aggregates of the green coumarin 6-loaded NPs, indicating that NPs have been internalized by 











      
 
       
Figure 4.9 Confocal laser scanning microscopy (CLSM) of Caco-2 cells incubated with the coumarin 
6-loaded PLA-TPGS/MMT NPs. The cell nuclei were stained by propidium iodide (red) and the 
uptake of fluorescence coumarin 6-loaded NPs (green) in the cells was visualized by overlaying 
images obtained by FITC filter and PI filter (a) image from FITC channel; (b) image from PI 




Figure 4.10 Confocal laser scanning microscopy (CLSM) of MCF-7 cells incubated with the 
coumarin 6-loaded PLA-TPGS/MMT NPs. The cell nuclei were stained by propidium iodide (red) 
and the uptake of fluorescence coumarin 6-loaded NPs (green) in the cells was visualized by 
overlaying images obtained by FITC filter and PI filter (a) image from FITC channel; (b) image 










 4.4 In vitro cell viability of NPs 
The in vitro cell cytotoxicity of the docetaxel-loaded nanoparticles were compared with that of 
taxotere in MCF-7 cell lines after incubating the cells with nanoparticles or taxotere for 24, 48 
and 72hours at different concentrations. The concentration range of docetaxel corresponds to the 
plasma level of the drug achievable. From figure 4.11, it is clear that the viability of MCF-7 cells 
treated with NPs did not show a significant difference compared to Taxotere® at lower 
concentrations, but the inhibiting activity of NPs increased with docetaxel concentration and 
demonstrated a significant difference at the highest concentration. Docetaxel is a schedule-
dependent drug acting on the cells at specific phase of cell cycle. Hence prolonged incubation of 
the cells with docetaxel-loaded NPs can kill both proliferating cells as well as non-proliferating 
cells. Cells incubated with Taxotere® acquire drug resistance due to P-gp action and hence are not 
as effective as drug-loaded NP formulations. This can be well demonstrated in the IC50 values. 
From the table 4.3, the IC50 values of PLA-TPGS NPs and PLA-TPGS/MMT NPs were less than 
half of Taxotere after 72 hours of incubation. Among the four NP formulations, PLGA NPs had 
the highest IC50 value because of comparatively lower uptake. PLGA/MMT NPs showed a 
slightly lower IC50 value than PLGA NPs and PLA-TPGS/MMT NPs proved to be highly 
cytotoxic with the lowest IC50 value (~ 3 times lower than Taxotere® ) at 24 hours. Higher 
uptake of nanoparticles and lower efflux of the drug has resulted in higher cytotoxicity of the 
nanoparticles compared to the commercial formulation of docetaxel. Moreover, the taxotere 
formulation vehicle itself possess some cytotoxic effect, whereas the placebo nanoparticles 





Figure 4.11  Viability of MCF-7 cancer cells cultured with docetaxel-loaded PLGA, PLGA/MMY, 




 Table 4.3  IC50 of MCF-7 cells after 24, 48, 72 hour incubation with docetaxel formulated in 














24  11.33  9.14  6.72  5.113  3.681 
48  0.626  2.8  0.54  0.22  0.140 
72  0.057  0.043  0.028  0.023  0.022 
 
 
4.5 In vivo pharmacokinetics 
The pharmacokinetic(PK) parameters were obtained by non-compartmental analysis. The PK 
parameters of the four nanoparticle formulations (PLGA, PLGA/MMT, PLA-TPGS and PLA-
TPGS/MMT NPs) administered orally are compared with oral taxotere.  
From table 4.4, it can be clearly concluded that in general, NP formulations have better 
performance in vivo than Taxotere®  when administered orally. The Area Under Curve (AUC0-inf ) 
is a measure of the amount of drug that has reached the systemic circulation. Taxotere®  was 
administered intravenously to group 1 rats inorder to determine the absolute AUC0-inf  value and 
this was used in the calculation of oral bioavailability of docetaxel in other formulations. The oral 
bioavailability of Taxotere®  was only 3.5% and this coincides with the previous research [64]. 
This proved that the NPs can efficiently cross the several gastro-intestinal barriers (i. degradation 
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 in stomach, ii. Mucosal barrier, iii. P-gp and CYP-450 enzyme action) and successfully been 
absorbed into the systemic circulation. 
From figure 4.12, it is clear that among the nanoparticle formulations, PLA-TPGS and PLA-
TPGS/MMT formulations have better pharmacokinetic parameters than PLGA and PLGA/MMT 
NP formulations. Several factors determine the in vivo performance of the nanoparticles. First 
and foremost, the drug encapsulation efficiency of PLGA and PLGA/MMT nanoparticles were 
low and this necessitated a larger volume of nanoparticles to be administered orally. The low oral 
bioavailability of PLGA NPs implies that it is not absorbed from the intestine fully. This may be 
because of the larger size of the PLGA NPs. These larger particles get entrapped in the mucus 
network and may be eliminated in the fecal matter during mucus clearance. The few smaller 
particles that manage to penetrate the mucus , get absorbed from the intestine and reach the 
systemic circulation. But then, due to its hydrophobic nature, the particles are cleared rapidly by 
the reticulo-endothelial system (RES). This leads to the poor bioavailability and low plasma half-
life of PLGA and PLGA/MMT NPs when compared to PLA-TPGS and PLA-TPGS/MMT NPs. 
The MMT coating on the NPs provides a mucoadhesive property and prevents the elimination 
through the alimentary canal. At the same time, the hydrophilic nature of TPGS chains on the NP 
surface and the smaller size of PLA-TPGS and PLA-TPGS/MMT NPs enable it to pass through 
the mucus network, unlike the PLGA and PLGA/MMT NPs that could have permanently adhered 
to the mucus network and eliminated during mucus clearance. 
Thus the mucoadhesive property of MMT and hydrophilic nature of PLA-TPGS copolymer could 
have acted synergistically resulting in a very high oral bioavailability of docetaxel in PLA-
TPGS/MMT NP formulation. 
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 The maximum concentration of docetaxel in plasma (Cmax) was highest in PLA-TPGS/MMT 
nanoparticles (1012.5ng/ml) which is well below the toxic level (2700ng/ml) [150]. This can be 
attributed to the presence of mucoadhesive MMT on the particles surface which increased the 
uptake of the particles in the intestine. This Cmax value was attained 4 hours (Tmax) after drug 
administration. The longer Tmax of PLA-TPGS/MMT nanoparticles compared to PLA-TPGS 
nanoparticles (2.5hrs) may be due to more slower and sustained drug release of PLA-TPGS/MMT 
nanoparticles which was evident from the invitro drug release profile. The sustained slow release 
from docetaxel-loaded PLA-TPGS/MMT NPs has kept the docetaxel plasma concentration within 
the therapeutic window for about 20 days. The minimum effective concentration (35 ng/ml) was 
determined from in vitro cytotoxicity assay of Taxotere in different human tumor cell lines [151]. 
From the PK profile, it was seen that the area under the curve (AUC0-inf) of PLA-TPGS and PLA-
TPGS/MMT nanoparticle were 25.3 (106419.8 ng.h/ml) and 21.68(90904.4 ng.h/ml)times that of 
taxotere(4192.7 ng.h/ml),respectively. This proved that the particles were successfully able to 
cross the intestinal barrier and reach the systemic circulation. The presence of TPGS on the 
particle surface increased the particle uptake by the intestinal cells by inhibiting P-gp action. 
Moreover, the TPGS coating on the nanoparticle surface prevents the uptake by macrophages as a 
result, the PLA-TPGS/MMT(118.8 hr) and the PLA-TPGS nanoparticles (92.6 hr) have a longer 
half life in plasma.  
Oral administration of Taxotere gave a low Cmax value (604.4 ng/ml), very short half life (6.9hrs) 
and hence low bioavailability (0.035). This was because of the efflux action of P-gp highly 
expressed in the intestinal lumen. The current formulations of docetaxel , PLA-TPGS and PLA-
TPGS/MMT nanoparticles, were successfully able to overcome the P-gp action and first pass 
metabolism. The absolute bioavailability of PLA-TPGS and PLA-TPGS/MMT nanoparticles 





Figure 4.12 In vivo pharmacokinetics- the plasma drug concentration versus time curve after i.v. 
injection of Taxotere® and oral delivery of NP formulation or Taxotere® to SD rats (n=5) at the same 
docetaxel concentration of 10 mg/kg. The concentration between the toxic level (2700 ng/ml) and 









 Table 4.4  Pharmacokinetics of docetaxel in SD rats. 












Cmax (ng/ml) 15497.4 604.4 450.1 567.9 919.4 1012.5 
Tmax (h) 0.5 2.5 2 4 2.5 4.5 
AUC0-inf 
(ng.h/ml) 
116557.6 4192.7 19015.0 24433.7 106419.8 90904.4 
T1/2 (h) 4.5 6.9 114.3 60 92.6 118.8 
MRT (h) 5.86 8.56 126.05 78.9 167.18 171.77 
Absolute 
Bioavailability 

















CHAPTER 5. CONCLUSIONS  
 
This research has successfully developed a novel mucoadhesive biodegradable nanoparticle 
system for oral  delivery of docetaxel. The PLA-TPGS/MMT nanoparticles were prepared by 
single emulsion method and were compared with the PLGA , PLGA/MMT NPs and taxotere for 
its cytotoxic activity in vitro and further the pharmacokinetics parameters of all the formulations 
have been determined in vivo. The fabricated nanoparticles were all in the range of 200-300nm in 
size with a negative surface charge. The presence of MMT slightly increased the size of 
nanoparticle. There was also an increase in the zeta potential due to the presence of MMT on the 
surface of PLA-TPGS/MMT and PLGA/MMT NPs. The MMT content in the nanoparticles was 
determined by thermogravimetric analysis. Further the physical status of the drug in all the 
nanoparticle formulation was found to be amorphous using thermal analysis. The nanoparticles 
were also tested for the drug release behavior in phosphate buffered saline. The release of 
docetaxel was biphasic with a initial burst release observed in all the nanoparticle formulations. 
The presence of MMT has slightly lowered the rate of release of drug in the steady phase which 
was due to slower degradation of the polymer in the presence of MMT. The uptake efficiency and 
in vitro cytotoxicity efficiency of all the nanoparticle formulations were compared with that of 
Taxotere® in Caco2 and MCF-7 cell lines. MMT and TPGS together increased the particle uptake 
and hence the cytotoxicity to the tumor cell lines. It was concluded that PLA-TPGS/MMT 
nanoparticles had better invitro cytotoxicity efficiency than other formulations. Following this, 
the in vivo pharmacokinetic study was done on Sprague Dawly rats for the four nanoparticle 
formulations and was compared with the pharmacokinetic parameters of Taxotere® administered 
via i.v as well as oral route. The oral bioavailability of the nanoparticles was atleast four fold 
(PLGA NPs) higher than that of Taxotere® and PLA-TPGS/MMT nanoparticles showed the 
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 highest oral bioavailability (78%) of docetaxel. Thus it can be concluded that PLA-TPGS/MMT 
NPs were able to efficiently deliver the drug to the systemic circulation and it was observed that 
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